| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology | ||
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology | ||
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology |
Recent Updates
Recently added Catalysts
Galmed Pharmaceuticals Ltd.$0.56
-0.04 (-6.68%)
C 44Pipeline Score Undervalued Pharma · Clinical
Market Cap
3.83 M
EPS
-2.33
P/E Ratio
-
Value Trade
54.19 K
-6.44 %
Week
-17.02 %
1 Month
1.77 %
3 Month
-26.48 %
6 Month
-99.88 %
5 Year
-99.98 %
All Time
Cash Data
Cash Position
12.35 K
Monthly Burn
12.35 K
Runway
12,345 mo
Overview
Volume
25.42 K
52 Week Range
0.41 - 2.34
% held by Insiders
3.07 %
% held by Institutions
4.15 %
Enterprise Value
-14.45 M
Total Shares
6.58 M
Short %
1.18 %
Float Shares
6.30 M
Company Description
locked
Upcoming Catalyst
Catalyst Timeline
Dated clinical, regulatory & corporate events for Galmed Pharmaceuticals Ltd.
414Total events
6Upcoming
85Tier-1 (high impact)
2013 – 2027Coverage
Upcoming catalysts 6
TBD
T2Timing Guidance
Real-life data from CG-100 patients planned to be submitted to FDA to support pivotal study
Event history 408
Jun 2, 2026
▲Preclinical PoCAramcholPreclinical
Combination of Aramchol Meglumine and PPARα agonist reduced fibrotic burden 4-fold in human cardiac organoids
cardiac fibrosissource ↗
Jun 2, 2026
▲Patent GrantedIP / Competition
New patent application filed based on combination therapy findings
cardiac fibrosissource ↗
Jun 2, 2026
●IND Enabling CompleteAramcholPreclinical
Preparations underway to support future IND-enabling activities
cardiac fibrosissource ↗
May 14, 2026
▲Topline ReadoutAramcholClinical Data
Topline results from Phase 1 PK study of Aramchol meglumine (AM) showing ~500% bioavailability increase vs Aramchol free acid 300mg
healthy subjectssource ↗
May 14, 2026
◆Trial InitiationAramcholTrial
Ongoing PK study comparing AM 400mg tablets once daily with AA 300mg tablets twice daily
healthy subjectssource ↗
May 6, 2026
▲Partnership / LicenseCorporate
Collaboration with Tissue Dynamics to develop human cardiac fibrosis model for Aramchol-based therapeutics
chronic cardiac fibrosissource ↗
Apr 14, 2026
▲Partnership / LicenseAramcholCorporate
Research collaboration agreement with Ramot at Tel Aviv University to evaluate Aramchol for metastatic brain cancer
metastatic brain cancersource ↗
Apr 9, 2026
▲Preclinical PoCAramcholPreclinical
In vitro data demonstrated Aramchol dose-dependently down-regulated αSyn-aggregation without toxicity
synucleinopathies (Parkinson disease, multiple systems atrophy, dementia with Lewy bodies)source ↗
Apr 9, 2026
▲Partnership / LicenseAramcholCorporate
Co-development of brain-penetrating Aramchol formulation with Barcode Nanotech
CNS diseasessource ↗
Q2 2026
◆Trial InitiationAramcholTrial
Plan to initiate PoC Phase 1b/2 study in PD patients in H2 2026
Parkinson diseasesource ↗
Drug Pipeline Intelligence
C44
Pipeline Score $42M
Pipeline ValueUndervalued
Valuation Signal5
Drugs Scored11.1x
rNPV / MCap Top 64%
Micro Cap (rank 329 of 911)
Percentile RankGalmed Pharmaceuticals Ltd. carries a moderate pipeline score (44/100), with $3.4B risk-adjusted pipeline value, led by Aramchol in Non-Alcoholic Fatty Liver Disease (Phase 2), across $176B in total addressable markets.
Showing 1 of 1 assets
| Drug | Indication | Phase | NCT ID | PTRS | rNPV | Status | Enrollment | Velocity | Design | Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Aramchol Small molecule | Fatty Liver | Phase 2 | NCT02279524 | 40% | $1.6B | COMPLETED | 247 | - | - | May 22, 2018 | - | Jul 14, 2021 |
Clinical Trial Results
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
Aramchol meglumine | oncology | Phase 1 | 2025-11-18 | In the Phase 1 AM-001 study, Aramchol meglumine 400mg and 200mg granules demonstrated a 5-fold and 3-fold increase in bioavailability, respectively, compared to Aramchol free acid 300mg tablets, suggesting improved dosing potential for future oncology trials. Read More | to our Report of Foreign Private Issuer on Form 6-K filed with the Securities and Exchange Commission ("SEC") on Read More | |
Aramchol meglumine | oncology | Phase 1 | 2025-11-18 | In the Phase 1 AM-001 study, Aramchol meglumine 400mg and 200mg granules demonstrated a 5-fold and 3-fold increase in bioavailability, respectively, compared to Aramchol free acid 300mg tablets, suggesting improved dosing potential for future oncology trials. Read More | to our Report of Foreign Private Issuer on Form 6-K filed with the Securities and Exchange Commission ("SEC") on Read More | |
Aramchol meglumine | oncology | Phase 1 | 2025-11-18 | In the Phase 1 AM-001 study, Aramchol meglumine 400mg and 200mg granules demonstrated a 5-fold and 3-fold increase in bioavailability, respectively, compared to Aramchol free acid 300mg tablets, suggesting improved dosing potential for future oncology trials. Read More | to our Report of Foreign Private Issuer on Form 6-K filed with the Securities and Exchange Commission ("SEC") on Read More |
Inside Trades
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Hedge Funds
Shares Held
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Hedge Funds invested in GLMD
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
GLMD Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Open interest
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
GLMDGalmed Pharmaceuticals Ltd. Announces Restructured Acquisition Terms for Colospan Ltd., Prioritizing CG-100 European Commercialization and Shareholder Value Protection and Consummation of Acquisition
Galmed Pharmaceuticals has restructured the acquisition of Colospan Ltd. to enhance shareholder value and expedite the commercialization of CG-100, a device aimed at improving colorectal surgery outcomes. The new terms include a cash payment and a performance-based earnout. With strong clinical data supporting CG-100, Galmed aims for a pan-European launch while managing risks associated with regulatory approvals and market conditions.
Read more →GLMD▼ -32.6%on this news
COLOSPAN LTD FINANCIAL STATEMENTS AS OF DECEMBER 31, 2025 CONTENTS Page Independent auditor's report 2 Balance sheets 3 Statements of operations 4 Statements of Convertible Preferred Shares and Shareholders' Deficit 5 St
Colospan Ltd. released its financial statements for the year ending December 31, 2025, revealing significant losses and ongoing concerns about its viability. The audit report notes recurring operational losses and a negative shareholders' equity. Despite having a total asset increase, the company reported a continued deficit and insufficient cash flow to support operations long-term. The audit highlights substantial doubts regarding the company's future sustainability.
Read more →GLMD▼ -32.6%on this news
Galmed Pharmaceuticals to Acquire Colospan to Create a GI-Focused Platform Targeting a $6 Billion Market
Galmed Pharmaceuticals has announced its acquisition of Colospan, a company specializing in medical devices for colorectal surgery. This strategic move aims to enhance Galmed's capabilities in addressing significant unmet needs in the field. The CG-100 device, designed to prevent anastomotic leaks, has received FDA Breakthrough Device Designation and is set for commercial launch in Europe. The acquisition is expected to close in Q2 2026.
Read more →GLMDTissue Dynamics and Galmed Unveil Unknown Metabolic Pathway for Cardiac Fibrosis and Heart Failure which Supports the Development of Aramchol for Cardiac Fibrosis
Tissue Dynamics and Galmed Pharmaceuticals have discovered a new metabolic pathway linked to cardiac fibrosis and heart failure. Their preclinical study showed that a combination of Aramchol Meglumine and a selective PPARα agonist significantly reduced fibrotic burden while preserving cardiac function. This advancement could lead to novel therapeutic approaches for treating cardiac fibrosis, addressing a significant unmet medical need.
Read more →GLMD▲ +10.6%on this news
Galmed Announces Results from First-in-Man Pharmacokinetics Study of Oral Formulation of Aramchol Meglumine (AM); 400mg AM Increases Bioavailability by ~500% in Comparison to Aramchol Free Acid (AA) 300mg
Galmed Pharmaceuticals has announced significant findings from its Phase 1 pharmacokinetics study of Aramchol meglumine (AM), highlighting a crucial dose transition to a once daily 400mg formulation that increases bioavailability by approximately 500% compared to Aramchol free acid (AA). The study supports upcoming clinical trials and may lower drug costs by around 50%, improving patient compliance. The company reinforces its intellectual property protection, aiding its competitive position in the liver diseases and gastrointestinal oncological markets. A subsequent study comparing AM with AA is underway to further validate these findings.
Read more →GLMD▲ +6.4%on this news
Tissue Dynamics and Galmed Pharmaceuticals to Develop Human-Centered Chronic Cardiac Fibrosis Platform to Advance Aramchol-Based Therapeutics
Tissue Dynamics and Galmed Pharmaceuticals have announced a collaboration to create a human-centered model for chronic cardiac fibrosis. This innovative platform aims to enhance the development of Aramchol-based therapies for heart diseases, particularly post-myocardial infarction remodeling and heart failure with preserved ejection fraction. The model will leverage advanced organoid technology and real-time monitoring to provide insights into cardiac fibrosis mechanisms.
Read more →GLMD▼ -6.7%on this news
Galmed Announces a Collaboration Agreement with Tel Aviv University to Evaluate its SCD1 inhibitor, Aramchol, as a Targeted Therapy for Metastatic Brain Cancers
Galmed Pharmaceuticals has entered into a collaboration agreement with Tel Aviv University to evaluate its brain-penetrating SCD1 inhibitor, Aramchol, for targeted therapy in metastatic brain cancer. The partnership aims to leverage genomic research and advanced modeling techniques to validate Aramchol's efficacy in treating tumors associated with p53 mutations. This collaboration highlights the need for effective treatments in a field characterized by poor patient prognoses and addresses significant unmet medical needs in cancer therapy. The findings may pave the way for innovative therapeutic options for this difficult-to-treat condition.
Read more →GLMD▲ +26.1%on this newsshared move
Galmed Announces the Breakthrough Development of a Brain Penetrating New Formulation of its SCD1 inhibitor, Aramchol
Galmed Pharmaceuticals has developed a new formulation of Aramchol that can penetrate the blood-brain barrier, potentially offering a treatment for Parkinson's disease and other CNS disorders. This formulation utilizes lipid nanoparticles for effective delivery and was co-developed with Barcode Nanotech. Preliminary data suggests that Aramchol may mitigate alpha-synuclein aggregation, a key factor in Parkinson's disease progression.
Read more →GLMDGalmed Pharmaceuticals Ltd. Files Annual Report on Form 20-F for the Fiscal Year Ended December 31, 2025
Galmed Pharmaceuticals Ltd. has filed its Annual Report on Form 20-F for the fiscal year ending December 31, 2025, with the SEC. The report details the company's ongoing development of Aramchol for liver diseases and its strategy to expand its product pipeline. Shareholders can access the report through the SEC's website or Galmed's Investor Relations site.
Read more →GLMD▼ -6.3%on this news
Galmed Pharmaceuticals Announces Receipt of Nasdaq Minimum Bid Price Notification
Galmed Pharmaceuticals has received a notification from Nasdaq indicating that it is not in compliance with the minimum bid price requirement of $1.00 per share. The company has a compliance period of 180 days to meet this requirement, failing which it may face delisting. The notification does not affect the current trading of its shares.
Read more →GLMD▼ -5.3%on this newsshared move
to our Report of Foreign Private Issuer on Form 6-K filed with the Securities and Exchange Commission ("SEC") on
Galmed Pharmaceuticals Ltd. received a notification from Nasdaq indicating that it is not in compliance with the minimum bid price requirement, which mandates a share price of at least $1.00. The company has a compliance period of 180 days to address this issue, during which its shares will continue to trade. If compliance is not achieved within this timeframe, Galmed may face delisting unless eligible for an extended time to meet other listing requirements. The situation poses risks for the company's market position and investor confidence.
Read more →GLMD▲ +8%on this news
Galmed Announces Acceptance of a Late-Breaking Abstract to be Presented at HEP-DART 2025 Meeting
Galmed Pharmaceuticals announced the acceptance of a late-breaking abstract for its drug candidate Aramchol at the HEP-DART 2025 Meeting. The abstract discusses the combination of Aramchol and regorafenib, which shows promise in treating hepatocellular carcinoma and other GI cancers. This research supports the initiation of a Phase 1/2 clinical trial set to begin in 2026.
Read more →GLMD▲ +5.6%on this newsshared move
Galmed Announces Grant of New Use Patents for the combination of Aramchol and Madrigal Pharmaceuticals' Rezdiffra (Resmetirom) for MASH
Galmed Pharmaceuticals has announced the grant of a new use patent for its drug candidate Aramchol in combination with Madrigal Pharmaceuticals' Rezdiffra for the treatment of MASH. This patent, granted in South Korea, extends patent protection to July 2042 and highlights the growing interest in combination therapies for NASH/MASH. The CEO emphasized the need for combination clinical studies due to the limitations of monotherapies.
Read more →GLMDGalmed Issues CEO Letter to Shareholders
Galmed Pharmaceuticals' CEO, Allen Baharaff, shared a letter to shareholders highlighting the company's recent achievements and future plans. The company is expanding its therapeutic focus for Aramchol beyond liver disease, aiming for advancements in oncology and cardiometabolic indications. With a solid cash position and ongoing clinical studies, Galmed is poised for growth despite the discontinuation of its ARMOR study.
Read more →GLMD▲ +12.4%on this newsshared move
Galmed Pharmaceuticals Reports Third Quarter 2025 Financial Results and Provides Business Update
Galmed Pharmaceuticals reported its financial results for Q3 2025, highlighting advancements in the development of Aramchol for liver and oncological diseases. The company is pursuing opportunities to diversify its product pipeline, particularly in cardiometabolic indications. However, it faces risks related to regulatory approvals and competition in the biopharmaceutical industry.
Read more →GLMDGalmed Announces Meaningful Top Line Results from AM-001 Study of Aramchol Meglumine
Galmed Pharmaceuticals announced promising top-line results from its AM-001 study of Aramchol meglumine. The study demonstrated a significant increase in bioavailability compared to Aramchol free acid tablets. This finding supports a once-daily dosing regimen, which may enhance patient adherence and reduce costs. The company plans to advance Aramchol into Phase 2 oncology studies in H1 2026.
Read more →GLMDGalmed Announces Top-line Results in Oncology MoA Studies: A 3-drug combination of Aramchol, Stivarga® and Metformin Significantly Enhanced GI Tumor Cells, Killing In-vivo and In-vitro
Galmed Pharmaceuticals announced positive top-line results from studies on Aramchol's efficacy in overcoming drug resistance in gastrointestinal cancers. The research, conducted in collaboration with Virginia Commonwealth University, demonstrated that Aramchol, when combined with Stivarga® and Metformin, significantly enhances anti-tumor effects. The company plans to initiate a Phase 1b study in early 2026 to further evaluate Aramchol's potential in oncology.
Read more →GLMDGalmed Pharmaceuticals Reports Second Quarter 2025 Financial Results and Provides Business Update
Galmed Pharmaceuticals Ltd. has reported its financial results for the second quarter of 2025, highlighting a net loss of $2.5 million. The company is focusing on the development of Aramchol for liver disease and expanding its pipeline into oncological indications. Despite the losses, Galmed's total assets have increased, and it is pursuing growth opportunities in cardiometabolic diseases.
Read more →GLMD▼ -5.4%on this newsshared move
Galmed Announces Digital Asset Management Strategy to Enhance Capital Efficiency and Drive Shareholder Value
Galmed Pharmaceuticals has announced a digital asset management strategy to enhance capital efficiency and shareholder value. The Board of Directors approved the establishment of a CryptoCommittee to oversee potential investments in digital assets, allocating up to 50% of cash reserves. This initiative aims to diversify the company's balance sheet and optimize treasury performance. Additionally, the authorized share capital has been increased to support future capital raising efforts.
Read more →GLMD▼ -5.4%on this newsshared move
to our Report of Foreign Private Issuer on Form 6-K to be filed with the Securities and Exchange Commission ("SEC") on
Galmed Pharmaceuticals Ltd. has announced the approval of a new digital asset management strategy aimed at enhancing capital efficiency. The Board has established a Crypto Committee to evaluate and oversee investments in digital assets, potentially allocating up to 50% of their cash reserves. The strategy is designed to optimize treasury performance and mitigate volatility while maintaining sufficient liquidity for operational needs. Additionally, the company's authorized share capital has been increased to allow for greater financial flexibility in pursuing strategic growth opportunities.
Read more →GLMDTHE COMPANIES LAW, 5759-1999 AMENDED AND RESTATED ARTICLES OF ASSOCIATION of GALMED PHARMACEUTICALS LTD " Preliminary 1. (a) In these Articles, unless the context otherwise requires: (a) An "Annual General Meeting" shall
Galmed Pharmaceuticals Ltd has released its amended and restated articles of association in accordance with the Companies Law, 5759-1999. The articles define various terms related to corporate governance, shareholder meetings, and share capital. They detail the rights and obligations of shareholders, including provisions for general meetings and shareholder resolutions. This represents a formal update to the company's governing documents, aligning them with current regulatory requirements.
Read more →GLMD▲ +6.5%on this news
Galmed Identifies Proprietary Biomarker Signature for Aramchol, Unlocking Multi-Billion-Dollar Expansion Potential Beyond NASH
Galmed Pharmaceuticals has announced the discovery of a proprietary blood-based biomarker signature for its lead candidate, Aramchol. This finding, derived from the Phase 3 ARMOR study, suggests that Aramchol may have therapeutic potential beyond liver diseases, potentially impacting cardiometabolic and inflammatory conditions. The biomarker insights are expected to facilitate regulatory discussions and inform future clinical trials.
Read more →GLMDGalmed Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides Business Update
Galmed Pharmaceuticals Ltd. reported its financial results for the first quarter of 2025, showing a slight improvement in net loss compared to the same period in 2024. The company raised a total of $6.5 million this year, boosting its cash balance to approximately $20.1 million. Notably, Galmed announced promising results regarding its oncology studies, highlighting the effectiveness of its drug Aramchol in combination with Bayer's Regorafenib. Despite this progress, the company continues to face financial challenges and uncertainties.
Read more →GLMDGalmed Reports Significant Anti-Fibrotic Effects of Aramchol in PSC Models
Galmed Pharmaceuticals has reported promising results for Aramchol, an SCD1 inhibitor, in pre-clinical models of primary sclerosing cholangitis (PSC), highlighting its significant potential to reduce biliary fibrosis. The treatment not only inhibited key hepatic fibrosis pathways but also showed improvements in clinical trials for liver fibrosis. With a strong safety profile noted in earlier studies, the company plans to push forward into further clinical evaluations targeting patients with biliary and hepatic cancers.
Read more →GLMD▲ +10.6%on this news
Galmed Announces First Time Results in Oncology Studies: Aramchol Significantly Enhances Bayer
Galmed Pharmaceuticals announced promising results from studies at Virginia Commonwealth University, where the combination of Aramchol and Bayer's Regorafenib exhibited significant reduction in hepatic tumor growth in mice models. The study detailed the mechanisms by which this drug combination enhances tumor cell death, with a Phase 1b study anticipated to begin in late 2025. The company plans to pursue this new oncology program alongside other developments in its pipeline.
Read more →GLMD▲ +6.4%on this news
Galmed Signed Term Sheet for the Development of Novel Semaglutide Sublingual Formulation
Galmed Pharmaceuticals Ltd. has signed a binding term sheet with Entomus s.r.o. for a license agreement concerning a novel sublingual formulation of Semaglutide. This Self-Emulsifying Drug Delivery System aims to improve drug absorption while offering a non-invasive administration method, potentially addressing the challenges associated with existing injectable and oral forms of the drug. With an expanding market for GLP-1 therapies projected to surpass $120 billion by 2030, Galmed is positioned to capitalize on this growth. However, the implementation is still contingent upon the completion of a definitive agreement and regulatory approval, amid existing patent expirations in some regions.
Read more →GLMDGalmed Pharmaceuticals Launches VCU Collaboration to Tackle Drug Resistance in GI Cancers
Galmed Pharmaceuticals has entered a collaboration with Virginia Commonwealth University (VCU) to explore the potential of Aramchol, an SCD1 inhibitor, in overcoming drug resistance in gastrointestinal cancers. This partnership targets advanced colorectal and liver cancers, leveraging recent research indicating lipid metabolism's role in treatment efficacy. The initiative is part of Galmed's strategic expansion into oncology and aims to provide novel solutions for cancers with high mortality rates. Should the collaboration yield positive results, it could significantly enhance Galmed's product pipeline and market position.
Read more →GLMD▲ +6%on this newsshared move
Galmed Unveils Novel Pharmacodynamic Blood Markers for Aramchol, the Most Clinically Advanced SCD1 Inhibitor
Galmed Pharmaceuticals has unveiled novel pharmacodynamic blood markers for its lead compound Aramchol, indicating its efficacy beyond treating NASH. The analysis from the Phase 3 ARMOR study shows promising effects on reducing markers of systemic inflammation, oxidative stress, and potential heart failure risks. This innovative biomarker strategy, developed in collaboration with Proteas Health, aims to strengthen clinical development efforts and expand the treatment's application in cardiometabolic and oncological indications. CEO Allen Baharaff has expressed optimism about these findings, emphasizing their potential to transform clinical practices.
Read more →GLMD▼ -11.3%on this newsshared move
Galmed Announces Positive Part 1 Results from the AM-001 Study of Aramchol Meglumine, an Enhanced Formulation of the Most Clinically Advanced SCD1 Inhibitor
Galmed Pharmaceuticals has announced positive preliminary results from Part 1 of the AM-001 study, which evaluated Aramchol Meglumine. The study indicates that this formulation has superior bioavailability compared to Aramchol free acid and may allow for a once-daily dosing regimen. These developments are a significant step in Galmed's transition towards further advancing Aramchol Meglumine in clinical trials for various diseases influenced by fatty acid metabolism. The transition has received FDA approval, highlighting a positive trajectory for the company's clinical program.
Read more →GLMD▲ +5.6%on this news
Galmed Pharmaceuticals Ltd. Files Annual Report on Form 20-F for the Fiscal Year Ended December 31, 2024
Galmed Pharmaceuticals Ltd., a clinical-stage biopharmaceutical company, has filed its Annual Report on Form 20-F with the SEC for the fiscal year ended December 31, 2024. The report is accessible on the SEC's website and will be provided to shareholders upon request. The company is focused on the development of its product Aramchol, targeting not only liver disease but also exploring additional oncological and cardiometabolic indications. However, the report includes cautionary statements regarding various risks and uncertainties that could affect the company's future results.
Read more →GLMDGalmed Pharmaceuticals Secures New Patent Grant Extending Aramchol
Galmed Pharmaceuticals announced the grant of a new patent for Aramchol, extending its patent protection through September 2039. This patent covers a combination therapy of Aramchol and Resmetirom for treating non-alcoholic steatohepatitis (NASH) and liver fibrosis. The company aims to capitalize on the growing market for NASH treatments, which is expected to significantly expand in the coming years. Galmed's strategy focuses on multi-modal approaches, enhancing their competitive position in the evolving NASH treatment landscape.
Read more →GLMD▼ -11.9%on this news
Galmed publishes Results from Aramchol Phase 3 Open Label part in Hepatology
Galmed Pharmaceuticals has published significant results from its Phase 3 Open Label study of Aramchol, showing its effectiveness in inducing anti-fibrotic effects in patients with MASH. The positive outcomes were validated through robust measurement techniques, including AI-enhanced digital pathology. The publication in 'Hepatology' underscores the drug's potential as a therapeutic option for fibrosis treatment. Galmed remains optimistic about Aramchol's unique mechanism and its role in combination therapies, although risks related to competition and regulatory approvals still exist.
Read more →GLMD▲ +11.3%on this newsshared move
GALMED PHARMACEUTICALS LTD. c/o Meitar Law Offices Abba Hillel Silver Rd., Ramat Gan, 5250608
Galmed Pharmaceuticals Ltd. is inviting shareholders to a Special General Meeting scheduled for October 14, 2024. This meeting, to be held at Meitar Law Offices in Ramat Gan, will address specific proposals, including an increase in authorized share capital. Shareholders are encouraged to present their proxies and are permitted to raise questions during the designated period. The board advises a 'FOR' vote on the proposed resolution to facilitate potential capital-raising opportunities.
Read more →GLMD▲ +21.7%on this news· ran to +36% by day 1shared move
Galmed Announces an Expansion of its Activities to Cancer and major Cardiometabolic Diseases
Galmed Pharmaceuticals has announced an expansion of its drug development efforts to include treatments for cancer and major cardiometabolic diseases, building on the success of their SCD1 inhibitor, Aramchol. The company plans to launch two new programs focused on overcoming resistance to oncological treatments and exploring new mechanisms targeting cardiac fibrosis. This shift comes after a cash infusion of $7.5 million and new scientific publications that underscore the therapeutic potential of SCD1 inhibition. Data from ongoing studies are expected to be released in the fourth quarter of 2024.
Read more →GLMDGalmed Pharmaceuticals Ltd. Files Annual Report on Form 20-F for the Fiscal Year Ended December 31, 2023
Galmed Pharmaceuticals Ltd. has filed its Annual Report on Form 20-F for the fiscal year ended December 31, 2023, with the U.S. SEC. The report highlights the company's ongoing efforts in the development of Aramchol for liver and fibro-inflammatory diseases. Shareholders can access the report through the SEC's website or request a free copy from the company's Investor Relations Department. The report discusses various forward-looking statements and associated risks that could affect the company's future operations and results.
Read more →GLMD▼ -12.6%on this news
Galmed Announces Grant of New Patent for the Combination of Aramchol with Resmetirom (MGL-3196, REZDIFFRA) for the Treatment of NASH and Liver Fibrosis
Galmed Pharmaceuticals Ltd. announced the grant of a European patent for the combination of Aramchol and Resmetirom, aimed at treating NASH and liver fibrosis. This patent was granted in several key European countries, and approval in the United States is pending. The new patent extends the protection of Aramchol until September 2039 and positions Galmed favorably within its therapeutic area. The company's CEO emphasized the potential of combination therapy to address complex liver conditions effectively. Galmed is focused on developing Aramchol specifically for liver-related diseases.
Read more →GLMD▲ +6.7%on this news· ran to -22% by day 3
Galmed Announces a delay in the initiation of its Primary Sclerosing Cholangitis (PSC) Phase 2a Study
Galmed Pharmaceuticals announced a delay of at least six months in the start of its Phase 2a study for Primary Sclerosing Cholangitis (PSC) due to unforeseen events related to the ongoing conflict in Israel. The company previously aimed to begin this study in the last quarter of 2023 but has now had to reassess its timeline. Delays in the Phase 1 pharmacokinetic study and new estimations depending on local and international partners are contributing factors to this setback. The CEO expressed commitment to working with partners to mitigate these delays.
Read more →GLMDGalmed Announces Allowance of New Patent for Aramchol for the Treatment of Pulmonary and Dermal Fibrosis
Galmed Pharmaceuticals Ltd. has announced the allowance of a new Japanese patent for its lead compound Aramchol, aimed at treating pulmonary and dermal fibrosis, expanding its patent protection until November 2037. This follows previously granted patents in Mexico and shows promise with significant anti-fibrotic effects evidenced in pre-clinical trials. With a focus on addressing the unmet needs in fibrotic diseases, Galmed aims to position Aramchol as a viable treatment option across various indications. Further patent approvals in the U.S. and globally are pending.
Read more →GLMDGALMED PHARMACEUTICALS LTD. 16 Tiomkin St. Tel Aviv 6578317, Israel
Galmed Pharmaceuticals Ltd. has announced the Special General Meeting of Shareholders scheduled for September 13, 2023. Shareholders are encouraged to vote on multiple proposals, including equity grants for executives. The company stresses the importance of shareholder participation and proper voting processes to ensure valid representation during the meeting.
Read more →GLMDONKAI, INC. CONSOLIDATED FINANCIAL STATEMENTS AS OF DECEMBER 31, 2022 U.S. DOLLARS IN THOUSANDS INDEX Page Consolidated Balance Sheets 3 Consolidated Statements of Operations 4 Consolidated Statements of Changes in Stock
Onkai Inc. released its audited consolidated financial statements for the year ending December 31, 2022. The audit concluded that the financial statements fairly represent the company's financial position and results of operations. However, the company reported a net loss of approximately $1.8 million and an accumulated deficit of $3.3 million. As a developmental stage company, Onkai anticipates continuing to incur significant operating losses as it works on its AI-based platform.
Read more →GLMD▼ -30.3%on this news
Galmed Pharmaceuticals Announces Pricing of $7 Million Public Offering
Galmed Pharmaceuticals has announced a public offering of $7 million consisting of 5.6 million ordinary shares and warrants. The offering, priced at $1.25 per share, is expected to close around July 18, 2023, subject to standard conditions. This funding is aimed at advancing the company's development of its lead drug, Aramchol, which targets liver diseases, including NASH. However, the company also faces several risks, including market competition and regulatory approvals that could affect future operations.
Read more →GLMDGalmed to employ OnKai
Galmed Pharmaceuticals has partnered with OnKai to enhance clinical trial methodologies using AI, starting with a study for Primary Sclerosing Cholangitis (PSC). This collaboration aims to include underserved communities and improve patient access to clinical trials. The Phase 2a study is set to commence at Virginia Commonwealth University in late 2023, which could lead to faster drug approvals and better site performance. OnKai's models, particularly TrialBridge, are designed to connect local clinics with specialized care and clinical trial opportunities.
Read more →GLMDGalmed Pharmaceuticals Reports First Quarter 2023 Financial Results and Recent Developments
Galmed Pharmaceuticals Ltd. reported its financial results for Q1 2023, reflecting a reduced net loss of $1.8 million compared to $6.1 million in Q1 2022. The company has initiated a clinical program for Aramchol meglumine focusing on Primary Sclerosing Cholangitis (PSC) and formed a partnership with Onkai, Inc. to enhance clinical diversity in trials. Additionally, Nasdaq notified Galmed that it has regained compliance with minimum bid price rules. However, their cash resources have decreased year-over-year.
Read more →GLMDGalmed Announces Initiation of a Clinical Development Program to Evaluate Aramchol meglumine for the Treatment of Primary Sclerosing Cholangitis (PSC)
Galmed Pharmaceuticals Ltd. has announced the start of a clinical program to evaluate Aramchol meglumine for treating Primary Sclerosing Cholangitis (PSC). This chronic liver disease, which impacts patients significantly, currently lacks approved therapies. The upcoming Phase 2 study will include approximately 15 patients and assess various treatment effects over 24 weeks. Experts involved, including Dr. Sayed Obaidullah Aseem and Prof. Arun Sanyal, express optimism about the potential insights this study could provide into PSC treatment approaches.
Read more →GLMDGalmed Pharmaceuticals forms a Strategic Partnership with OnKai
Galmed Pharmaceuticals Ltd. has announced a strategic partnership with OnKai Inc. through a $3M equity investment. This collaboration aims to leverage OnKai's AI-powered platform to enhance clinical trial recruitment, particularly among underserved patient populations. The partnership seeks to address challenges in obtaining diverse patient representation in clinical studies while providing innovative treatment access. The joint efforts are expected to improve both the efficiency and effectiveness of future clinical trials.
Read more →GLMDGalmed Pharmaceuticals Ltd. Files Annual Report on Form 20-F for the Fiscal Year Ended December 31, 2022
Galmed Pharmaceuticals Ltd. announced the filing of its Annual Report on Form 20-F for the fiscal year ending December 31, 2022, with the SEC. The report is available for shareholders at no charge, demonstrating transparency and commitment to stakeholder communication. The company is focused on developing Aramchol for liver diseases and is collaborating with the Hebrew University on a new peptide. Despite these advancements, Galmed faces uncertainties regarding regulatory actions and competition in the biopharmaceutical market.
Read more →GLMDGalmed Announces Issuance of New Composition of Matter Patent for Aramchol meglumine Salt
Galmed Pharmaceuticals announced the issuance of a new patent for Aramchol meglumine salt by the USPTO, securing its commercial exclusivity until December 2034. This patent not only extends the intellectual property protection for Aramchol but also applies to its therapeutic use in treating conditions such as NASH and Fibrosis. The company reports a robust patent portfolio with over 20 issued patents globally. The CEO highlighted that this strengthens their potential to maximize Aramchol's therapeutic capabilities across various indications.
Read more →GLMD▲ +9.3%on this news
Galmed reports results from the Open-Label part of the ARMOR study showing improvements in histology, imaging, and biomarkers with Aramchol
Galmed Pharmaceuticals announced positive results from the Open-Label part of the ARMOR study, showing significant improvements in fibrosis and liver health indicators in subjects treated with Aramchol. The study enrolled 157 subjects and highlighted a remarkable reduction in fibrosis scores, liver stiffness, and biochemical markers of liver injury. Galmed plans to discuss the findings with the FDA to enhance measurement methodologies for clinical studies. However, the company has decided against initiating the Double-Blind part of the study at this time, pending strategic evaluations.
Read more →GLMDGalmed Pharmaceuticals Ltd. (NASDAQ: GLMD) Announces Receipt of Extension to Meet the Nasdaq
TEL AVIV, Israel, Dec. 14, 2022 /PRNewswire/ -- Galmed Pharmaceuticals Ltd. (Nasdaq: GLMD) ("Galmed" or the "Company"), a biopharmaceutical company focused on the development of Aramchol and Amilo-5MER, announced today that on December 13, 2022, it received a letter from The Nasd
Read more →GLMD▼ -9.5%on this news
Galmed Pharmaceuticals Provides Business Update and Reports Second Quarter 2022 Financial Results
TEL AVIV, Israel, Aug. 4, 2022 /PRNewswire/ -- Galmed Pharmaceuticals Ltd. (Nasdaq: GLMD) ("Galmed" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of Aramchol™, an oral therapy for the treatment of nonalcoholic steatohepatitis, or NASH, f
Read more →GLMDGalmed Reports Significant Anti-Fibrotic Effects of Aramchol in a Lung Fibrosis Model
Statistically significant clinical and histology improvements were also demonstrated in a model of inflammatory bowel disease (IBD) Data reinforcing the expansion of Aramchol's Clinical Development to Additional Indications TEL AVIV, Israel, July 7, 2022 /PRNewswire/ -- Galmed
Read more →GLMDGalmed Pharmaceuticals Reports First Quarter 2022 Financial Results
TEL AVIV, Israel, May 17, 2022 /PRNewswire/ —Galmed Pharmaceuticals Ltd. (Nasdaq: GLMD) ("Galmed" or the "Company"), a clinical-stage biopharmaceutical company for liver, metabolic, fibrosis and inflammatory diseases reports financial results for the three months ended March 31,
Read more →GLMDGalmed updates business and clinical development strategy to better leverage Aramchol
Recent data reinforce the anti-fibrotic activity of Aramchol previously observed in a wide range of pre-clinical models, in addition to the known effects in liver fibrosis The Open-Label Part of the ARMOR study met its objectives demonstrating consistent anti-fibrotic effects at
Read more →GLMDGalmed updates business and clinical development strategy to better leverage Aramchol's anti-fibrotic effects Recent data reinforce the anti-fibrotic activity of Aramchol previously observed in a wide range of pre-clinic
updates business and clinical development strategy to better leverage Aramchol's anti-fibrotic effects Recent data reinforce the anti-fibrotic activity of Aramchol previously observed in a wide range of pre-clinical models, in addition to the known effects in liver fibrosis
Read more →GLMDGalmed Pharmaceuticals Provides Business Update and Reports Fourth Quarter and Year End 2021 Financial Results
- Conference Call and Webcast Today at 8:30 a.m. ET / 5:30 a.m. PT - TEL AVIV, Israel, May 2, 2022 /PRNewswire/ -- Galmed Pharmaceuticals Ltd. (NASDAQ: GLMD) ("Galmed" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of the liver targeted
Read more →GLMDGalmed reports interim results from the Open-Label part of the ARMOR study with Aramchol showing robust fibrosis improvement across multimodality histological assessment
- Treatment with Aramchol 300mg BID resulted in a high rate of subjects with fibrosis improvement using NASH CRN, paired ranked reading and Artificial Intelligence (AI) quantitative digital analysis. - At week 48, both paired and AI evaluations identified more subjects with fibr
Read more →GLMDGalmed Pharmaceuticals to Report Fourth Quarter and Year End 2021 Financial Results and Provide Business Update on Monday May 2
TEL AVIV, Israel, April 26, 2022 /PRNewswire/ -- Galmed Pharmaceuticals Ltd. (Nasdaq: GLMD) ("Galmed" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of Aramchol, a liver targeted, oral, SCD1 modulator, currently in Phase 3 clinical trial
Read more →GLMDGalmed Continues to Drive Innovation with Three New US Patents Granted for Aramchol and its Meglumine Salt
TEL AVIV, Israel, Jan. 11, 2022 /PRNewswire/ -- Galmed Pharmaceuticals Ltd. (NASDAQ-CM: GLMD) ("Galmed" or the "Company"), a clinical-stage biopharmaceutical company for liver, metabolic and inflammatory diseases announced today that the United States Patent and Trademark Office
Read more →GLMDGalmed announces positive results of Phase 1 study of Amilo-5MER
TEL AVIV, Israel, Jan. 10, 2022 /PRNewswire/ -- Galmed Pharmaceuticals Ltd. (Nasdaq: GLMD) ("Galmed" or the "Company"), a clinical-stage biopharmaceutical company for liver, metabolic and inflammatory diseases announced today results of a Phase 1 clinical trial of Amilo-5MER in h
Read more →GLMDGalmed Pharmaceuticals Provides Additional Positive Data from the Open Label Part of ARMOR Study and Reports Third Quarter 2021 Financial Results
TEL AVIV, Israel, Nov. 8, 2021 /PRNewswire/ -- Galmed Pharmaceuticals Ltd. (Nasdaq: GLMD) ("Galmed" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of the liver targeted SCD1 modulator Aramchol™, an oral therapy for the treatment of nonalc
Read more →GLMDGalmed Announces New Positive Data from Ongoing ARMOR Study Open Label Part Showing Clinically Significant Effect on Fibrosis Improvement
-- Updated liver histology data from first 20 patients show 60% fibrosis improvement by at least 1 stage as early as 24 weeks, data will be presented at AASLD Late Breaker Presentations -- -- Statistically significant reductions in biomarkers associated with liver fibrosis inclu
Read more →GLMDGalmed Announces Positive Results from First 16 Patients in Open-Label Part of ARMOR Study
TEL AVIV, Israel, Nov. 1, 2021 /PRNewswire/ -- Galmed Pharmaceuticals Ltd. (Nasdaq: GLMD) ("Galmed" or the "Company"), a clinical-stage biopharmaceutical company for liver, metabolic and inflammatory diseases announced today results from the first 16 patients in the Open-Label Pa
Read more →GLMDResults of Galmed
TEL AVIV, Israel, October 11, 2021 /PRNewswire/ -- Galmed Pharmaceuticals Ltd. (Nasdaq: GLMD) ("Galmed" or the "Company"), a clinical-stage biopharmaceutical company for liver, metabolic and inflammatory diseases announced today that the one-year results of the global Phase 2b ra
Read more →GLMDGalmed Pharmaceuticals Announces Publication in "The Journal of Autoimmunity" for its IND ready, Amilo-5MER, a specific anti-inflammatory compound
TEL AVIV, Israel, Aug. 19, 2021 /PRNewswire/ -- Galmed Pharmaceuticals Ltd. (Nasdaq: GLMD) ("Galmed" or the "Company"), a clinical-stage biopharmaceutical company for liver, metabolic and inflammatory diseases announced today the publication in The Journal of Autoimmunity for its
Read more →GLMDMHRA Agrees with Galmed
TEL AVIV, Israel, Aug. 16, 2021 /PRNewswire/ -- Galmed Pharmaceuticals Ltd. (Nasdaq: GLMD) ("Galmed" or the "Company"), a clinical-stage biopharmaceutical company for liver, metabolic and inflammatory diseases announced today that the Medicines and Healthcare products Regulatory
Read more →GLMDGalmed Pharmaceuticals Provides Business Update and Reports Second Quarter 2021 Financial Results
TEL AVIV, Israel, Aug. 5, 2021 /PRNewswire/ -- Galmed Pharmaceuticals Ltd. (Nasdaq: GLMD) ("Galmed" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of the liver targeted SCD1 modulator Aramchol™, an oral therapy for the treatment of nonalc
Read more →GLMDFDA Agrees with Galmed
TEL AVIV, Israel, Aug. 2, 2021 /PRNewswire/ -- Galmed Pharmaceuticals Ltd. (Nasdaq: GLMD) ("Galmed" or the "Company"), a clinical-stage biopharmaceutical company for liver, metabolic and inflammatory diseases announced today that the FDA agreed with its plan to use Aramchol meglu
Read more →GLMDGalmed Pharmaceuticals to Report Second Quarter 2021 Financial Results and Provide Business Update on Thursday August 5
TEL AVIV, Israel, July 29, 2021 /PRNewswire/ -- Galmed Pharmaceuticals Ltd. (Nasdaq: GLMD) ("Galmed" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of Aramchol, a liver targeted, oral, SCD1 modulator, currently in Phase 3 clinical trial f
Read more →GLMDGalmed Pharmaceuticals Provides Business Updates and Reports First Quarter 2021 Financial Results
TEL AVIV, Israel, May 13, 2021 /PRNewswire/ -- Galmed Pharmaceuticals Ltd. (Nasdaq: GLMD) ("Galmed" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of the liver targeted SCD1 modulator Aramchol™, an oral therapy for the treatment of nonalc
Read more →GLMDGalmed Pharmaceuticals to Report First Quarter 2021 Financial Results and Provide Business Update on Thursday May 13
TEL AVIV, Israel, May 6, 2021 /PRNewswire/ -- Galmed Pharmaceuticals Ltd. (Nasdaq: GLMD) ("Galmed" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of Aramchol, a liver targeted, oral, SCD1 modulator, currently in Phase 3 clinical trial for
Read more →GLMDGalmed Announces Approval of IND Application in China for Aramchol for the Treatment of NASH & Fibrosis in the Global Phase 3 ARMOR Registrational Study
TEL AVIV, Israel, May 3, 2021 /PRNewswire/ -- Galmed Pharmaceuticals Ltd. (Nasdaq: GLMD) ("Galmed" or the "Company"), a clinical-stage biopharmaceutical company for liver, metabolic and inflammatory diseases announced today that the National Medical Products Administration (NMPA)
Read more →GLMDGalmed Pharmaceuticals Provides Business Update and Reports Fourth Quarter and Year End 2020 Financial Results
TEL AVIV, Israel, March 18, 2021 /PRNewswire/ -- Galmed Pharmaceuticals Ltd. (Nasdaq: GLMD) ("Galmed" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of the liver targeted SCD1 modulator Aramchol™, an oral therapy for the treatment of nona
Read more →GLMDGalmed Pharmaceuticals Announces Dosing of First Subject in First in Human Phase 1 Trial of Amilo-5MER
TEL AVIV, Israel, March 16, 2021 /PRNewswire/ -- Galmed Pharmaceuticals Ltd. (Nasdaq: GLMD) ("Galmed" or the "Company"), a clinical-stage biopharmaceutical company today announced the treatment of the first subject in the First-in-Human Phase I clinical trial evaluating Amilo-5ME
Read more →GLMDGalmed Pharmaceuticals to Report Fourth Quarter and Year End 2020 Financial Results and Provide Business Update on Thursday March 18
TEL AVIV, Israel, March 11, 2021 /PRNewswire/ -- Galmed Pharmaceuticals Ltd. (Nasdaq: GLMD) ("Galmed" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of Aramchol, a liver targeted, oral, SCD1 modulator, currently in Phase 3 clinical trial
Read more →GLMDTHE COMPANY Except as otherwise indicated herein or as the context otherwise requires, references to the "Company," "Galmed," "we," "us," "our" or similar references mean Galmed Pharmaceuticals Ltd., a corporation formed
Except as otherwise indicated herein or as the context otherwise requires, references to the "Company," "Galmed," "we," "us," "our" or similar references mean Galmed Pharmaceuticals Ltd., a corporation formed under the laws of the State of Israel, and its subsidiaries, and (ii
Read more →GLMDGalmed Pharmaceuticals Announces Pricing of $10 Million Public Offering of Ordinary Shares
TEL AVIV, Israel, Feb. 16, 2021 /PRNewswire/ -- Galmed Pharmaceuticals Ltd. (Nasdaq: GLMD) ("Galmed" or the "Company"), a clinical-stage biopharmaceutical company for liver, metabolic and inflammatory diseases, today announced the pricing of the underwritten public offering of 2,
Read more →GLMDGalmed Pharmaceuticals Announces Proposed Offering of Ordinary Shares
TEL AVIV, Israel, Feb. 16, 2021 /PRNewswire/ -- Galmed Pharmaceuticals Ltd. (Nasdaq: GLMD) ("Galmed" or the "Company"), a clinical-stage biopharmaceutical company for liver, metabolic and inflammatory diseases, today announced that it is commencing an underwritten public offering
Read more →GLMDGalmed Pharmaceuticals Announces Upcoming Publication in JHEP Reports of New Data Supporting Aramchol
TEL AVIV, Israel, Jan. 26, 2021 /PRNewswire/ -- Galmed Pharmaceuticals Ltd. (Nasdaq: GLMD) ("Galmed" or the "Company"), a clinical-stage biopharmaceutical company for liver, metabolic and inflammatory diseases, today announced upcoming publication of a paper entitled "Aramchol Do
Read more →GLMDGalmed Hosting KOL Symposium and Pipeline Update
TEL AVIV, Israel, Jan. 19, 2021 /PRNewswire/ -- Galmed Pharmaceuticals Ltd. (Nasdaq: GLMD) ("Galmed" or the "Company"), a clinical-stage biopharmaceutical company for liver, metabolic and inflammatory diseases, announced today that it will host a Key Opinion Leader (KOL) symposiu
Read more →GLMDGalmed to add Open Label Part to ARMOR Study; First Read-out Expected in Q4 2021
TEL AVIV, Israel, Dec. 17, 2020 /PRNewswire/ -- Galmed Pharmaceuticals Ltd. (Nasdaq: GLMD) ("Galmed" or the "Company"), a clinical-stage biopharmaceutical company for liver, metabolic and inflammatory diseases announced today the addition of an open-label part to its ARMOR Phase
Read more →GLMDGalmed Pharmaceuticals Reports Third Quarter 2020 Financial Results
TEL AVIV, Israel, Nov. 12, 2020 /PRNewswire/ -- Galmed Pharmaceuticals Ltd. (Nasdaq: GLMD) ("Galmed" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of the liver targeted SCD1 modulator Aramchol™, an oral therapy for the treatment of nonal
Read more →GLMDGalmed and MyBiotics to Collaborate in Development of Bespoke Microbiome Signature for Aramchol Collaboration Seeks to Enhance Response Rate and Identify Biomarker for Treatment of NASH and Fibrosis TEL AVIV and Rehovot
MyBiotics to Collaborate in Development of Bespoke Microbiome Signature for Aramchol Rehovot Israel, November 9, 2020 - Galmed Pharmaceuticals Ltd. (Nasdaq: GLMD) and MyBiotics Pharma Ltd. announced today they have entered into a research and development collaboration agreement
Read more →GLMDGalmed Pharmaceuticals to Report Third Quarter 2020 Financial Results and Provide Business Update on Thursday November 12
TEL AVIV, Israel, Nov. 5, 2020 /PRNewswire/ -- Galmed Pharmaceuticals Ltd. (Nasdaq: GLMD) ("Galmed" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of Aramchol, a liver targeted, oral, SCD1 modulator, currently in Phase 3 clinical trial fo
Read more →GLMDGalmed and Gannex Expand Development Programs For NASH Through Research Collaboration of Aramchol and ASC41 (THR-beta Agonist)
TEL-AVIV, Israel and SHANGHAI, Sept. 10, 2020 /PRNewswire/ -- Gannex Pharma Co., Ltd., a wholly owned company of Ascletis Pharma Inc. (HKEX: 1672) and Galmed Pharmaceuticals Ltd. (NASDAQ: GLMD) announces today that they have entered into a research agreement aiming at combination
Read more →GLMDGannex and Galmed Expand Development Programs For NASH Through Research Collaboration of Aramchol and ASC41 (THR-beta Agonist) Shanghai, China and Tel-Aviv, Israel
Gannex and Galmed Expand Development Programs For NASH Through Research Collaboration of Aramchol and ASC41 (THR-beta Agonist) Shanghai, China and Tel-Aviv, Israel Sept. 9, 2020 -- Gannex Pharma Co. Ltd, a wholly owned company of Ascletis Pharma Inc (HKEX:1672) and Galmed Pha
Read more →GLMDGalmed Pharmaceuticals Announces Acceleration of its New Clinical Amilo-5MER program
TEL AVIV, Israel, Aug. 6, 2020 /PRNewswire/ -- Galmed Pharmaceuticals Ltd. (Nasdaq: GLMD) ("Galmed" or the "Company"), a clinical-stage biopharmaceutical company for liver, metabolic and inflammatory diseases provides today updated information on the Company's pipeline program.
Read more →GLMDGalmed Pharmaceuticals Provides Business Update and Reports Second Quarter 2020 Financial Results
TEL AVIV, Israel, Aug. 6, 2020 /PRNewswire/ -- Galmed Pharmaceuticals Ltd. (Nasdaq: GLMD) ("Galmed" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of the liver targeted SCD1 modulator Aramchol™, an oral therapy for the treatment of nonalc
Read more →GLMDGalmed Pharmaceuticals to Report Second Quarter 2020 Financial Results and Provide Business Update on Thursday August 6
TEL AVIV, Israel, July 30, 2020 /PRNewswire/ -- Galmed Pharmaceuticals Ltd. (Nasdaq: GLMD) ("Galmed" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of Aramchol, a liver targeted, oral, SCD1 modulator, currently in a Phase 3 clinical trial
Read more →GLMDGalmed Pharmaceuticals Provides Business Update and Reports First Quarter 2020 Financial Results
TEL AVIV, Israel, May 14, 2020 /PRNewswire/ --Galmed Pharmaceuticals Ltd. (Nasdaq: GLMD) ("Galmed" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of the liver targeted SCD1 modulator Aramchol™, an oral therapy for the treatment of nonalco
Read more →GLMDGalmed Pharmaceuticals to Report First Quarter 2020 Financial Results and Provide Business Update on Thursday May 14
TEL AVIV, Israel, May 7, 2020 /PRNewswire/ -- Galmed Pharmaceuticals Ltd. (Nasdaq: GLMD) ("Galmed" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of Aramchol, a liver targeted, oral, SCD1 modulator, currently in Phase 3 clinical trial for
Read more →GLMDGalmed Pharmaceuticals Provides Business Update and Reports Fourth Quarter and Year End 2019 Financial Results
TEL AVIV, Israel, March 12, 2020 /PRNewswire/ -- Galmed Pharmaceuticals Ltd. (Nasdaq: GLMD) ("Galmed" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of Aramchol, a liver targeted, oral, SCD1 modulator, currently in a Phase 3 clinical tria
Read more →GLMDGalmed Pharmaceuticals to Report Fourth Quarter and Year End 2019 Financial Results and Provide Business Update on Thursday March 12
TEL AVIV, Israel, March 5, 2020 /PRNewswire/ -- Galmed Pharmaceuticals Ltd. (Nasdaq: GLMD) ("Galmed" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of Aramchol, a liver targeted, oral, SCD1 modulator, currently in Phase 3 clinical trial f
Read more →GLMDGalmed Pharmaceuticals Provides Business Update and Reports Third Quarter 2019 Financial Results
TEL AVIV, Israel, Nov. 6, 2019 /PRNewswire/ -- Galmed Pharmaceuticals Ltd. (Nasdaq: GLMD) ("Galmed" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of Aramchol, a liver targeted, oral SCD1 modulator currently in a Phase 3/4 clinical trial
Read more →GLMDGalmed Pharmaceuticals to Present New Data on Aramchol Effect on Glucose Metabolism, MoA and Clinical Results at AASLD 2019
TEL AVIV, Israel, Oct. 31, 2019 /PRNewswire/ -- Galmed Pharmaceuticals Ltd. (Nasdaq: GLMD) ("Galmed" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of Aramchol, a liver targeted, oral, SCD1 modulator, currently in Phase 3/4 clinical trial
Read more →GLMDGalmed Pharmaceuticals to Report Third Quarter 2019 Financial Results and Provide Business Update on Wednesday, November 6
TEL AVIV, Israel, Oct. 30, 2019 /PRNewswire/ -- Galmed Pharmaceuticals Ltd. (Nasdaq: GLMD) ("Galmed" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of Aramchol, a liver targeted, oral, SCD1 modulator, currently in Phase 3/4 clinical trial
Read more →GLMDGalmed Pharmaceuticals Initiated ARMOR, a Phase 3/4 Registrational Study of Aramchol in Subjects With NASH and Fibrosis
TEL AVIV, Israel, Sept. 26, 2019 /PRNewswire/ -- Galmed Pharmaceuticals Ltd. (Nasdaq: GLMD) ("Galmed" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of the liver targeted SCD1 modulator Aramchol, an oral therapy for the treatment of nonal
Read more →GLMDGalmed Pharmaceuticals Provides Business Update and Reports Second Quarter 2019 Financial Results
TEL AVIV, Israel, Aug. 5, 2019 /PRNewswire/ -- Galmed Pharmaceuticals Ltd. (Nasdaq: GLMD) ("Galmed" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of the liver targeted SCD1 modulator Aramchol, a once-daily, oral therapy for the treatment
Read more →GLMDGalmed Pharmaceuticals to Report Second Quarter 2019 Financial Results and Provide Business Update on Monday, August 5
TEL AVIV, Israel, July 29, 2019 /PRNewswire/ -- Galmed Pharmaceuticals Ltd. (Nasdaq: GLMD) ("Galmed" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of the liver targeted SCD1 modulator, Aramchol, an oral therapy for the treatment of nonal
Read more →GLMDGalmed Pharmaceuticals Provides Business Update and Reports First Quarter 2019 Financial Results
TEL AVIV, Israel, May 7, 2019 /PRNewswire/ -- Galmed Pharmaceuticals Ltd. (Nasdaq: GLMD) ("Galmed" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of the liver targeted SCD1 modulator Aramchol™, an oral therapy for the treatment of nonalco
Read more →GLMDGalmed Pharmaceuticals to Report First Quarter 2019 Financial Results and Provide Business Update on Tuesday, May 7
TEL AVIV, Israel, April 30, 2019 /PRNewswire/ -- Galmed Pharmaceuticals Ltd. (Nasdaq: GLMD) ("Galmed" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of the liver targeted SCD1 modulator, Aramchol, an oral therapy for the treatment of nona
Read more →GLMDGalmed Pharmaceuticals Announces Successful Completion of End of Phase 2 Meeting With FDA and Plan for Start of Phase 3
TEL AVIV, Israel, April 9, 2019 /PRNewswire/ -- Galmed Pharmaceuticals Ltd. (Nasdaq: GLMD) ("Galmed" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of the liver targeted SCD1 modulator, Aramchol, an oral therapy for the treatment of nonal
Read more →GLMDGalmed Pharmaceuticals Reports Fourth Quarter and Full Year 2018 Financial Results and Provides Business Update
TEL AVIV, Israel, March 13, 2019 /PRNewswire/ -- Galmed Pharmaceuticals Ltd. (Nasdaq: GLMD) ("Galmed" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of the liver targeted SCD1 modulator Aramchol, an oral therapy for the treatment of nonal
Read more →GLMDGalmed Reports Positive Results From Pharmacokinetic Split Dose Study of Aramchol
TEL AVIV, Israel, March 12, 2019 /PRNewswire/ -- Galmed Pharmaceuticals Ltd. (Nasdaq: GLMD) ("Galmed" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of the liver targeted SCD1 modulator, Aramchol, an oral therapy for the treatment of nona
Read more →GLMDGalmed Pharmaceuticals to Report Fourth Quarter and Year End 2018 Financial Results and Provide Business Update on Wednesday, March 13
TEL AVIV, Israel, March 6, 2019 /PRNewswire/ -- Galmed Pharmaceuticals Ltd. (NASDAQ: GLMD) ("Galmedˮ or the "Company"), a clinical-stage biopharmaceutical company focused on the development of the liver targeted SCD1 modulator Aramchol, a once-daily, oral therapy for the treatmen
Read more →GLMDPhase 2 Data for Galmed Pharmaceutical
TEL AVIV, Israel, Nov. 13, 2018 /PRNewswire/ -- Galmed Pharmaceuticals Ltd. (Nasdaq: GLMD) ("Galmed" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of the liver targeted SCD1 modulator Aramchol, a once-daily, oral therapy for the treatmen
Read more →GLMDGalmed Pharmaceuticals Provides Business Update and Reports Third Quarter 2018 Financial Results
TEL AVIV, Israel, Nov. 5, 2018 /PRNewswire/ -- Galmed Pharmaceuticals Ltd. (Nasdaq: GLMD) ("Galmed" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of the liver targeted SCD1 modulator Aramchol, a once-daily, oral therapy for the treatment
Read more →GLMDGalmed Pharmaceuticals to Report Third Quarter 2018 Financial Results and Provide Business Update on Monday, November 5
TEL AVIV, Israel, Oct. 29, 2018 /PRNewswire/ -- Galmed Pharmaceuticals Ltd. (Nasdaq: GLMD) ("Galmedˮ or the "Company"), a clinical-stage biopharmaceutical company focused on the development of the liver targeted SCD1 modulator Aramchol™, a once-daily, oral therapy for the treatme
Read more →GLMDGalmed Pharmaceuticals Announces a Late-Breaking Abstract on Aramchol™ to be Presented at the American Association for the Study of Liver Diseases (AASLD) - The Liver Meeting®
TEL AVIV, Israel, Oct. 2, 2018 /PRNewswire/ -- Galmed Pharmaceuticals Ltd. (Nasdaq: GLMD) ("Galmed" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of the liver targeted SCD1 modulator Aramchol™, a once-daily, oral therapy for the treatmen
Read more →GLMDGalmed Pharmaceuticals to Present at the Cantor Global Healthcare Conference, ROTH Battle of the NASH Thrones Investor Conference and Stifel Healthcare Conference
TEL AVIV, Israel, Sept. 27, 2018 /PRNewswire/ -- Galmed Pharmaceuticals Ltd. (Nasdaq: GLMD), a clinical-stage biopharmaceutical company focused on the development of the liver targeted SCD1 modulator Aramchol™, a once-daily, oral therapy for the treatment of nonalcoholic steatohe
Read more →GLMDGalmed Pharmaceuticals Provides Business Update and Reports Second Quarter 2018 Financial Results
TEL AVIV, Israel, Aug. 2, 2018 /PRNewswire/ -- Galmed Pharmaceuticals Ltd. (Nasdaq: GLMD) ("Galmed" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of the liver targeted SCD1 modulator Aramchol, a once-daily, oral therapy for the treatment
Read more →GLMDGalmed Pharmaceuticals to Report Second Quarter 2018 Financial Results and Provide Business Update on Thursday, August 2
TEL AVIV, Israel, July 26, 2018 /PRNewswire/ -- Galmed Pharmaceuticals Ltd. (Nasdaq: GLMD) ("Galmedˮ or the "Company"), a clinical-stage biopharmaceutical company focused on the development of the liver targeted SCD1 modulator Aramchol™, a once-daily, oral therapy for the treatme
Read more →GLMDGalmed Pharmaceuticals Ltd. Announces Pricing of Public Offering of Ordinary Shares
TEL AVIV, Israel, June 19, 2018 /PRNewswire/ -- Galmed Pharmaceuticals Ltd. (Nasdaq: GLMD) ("Galmed" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of the liver targeted SCD1 modulator Aramchol™, a once-daily, oral therapy for the treatme
Read more →GLMDJune 2018 Safe Harbor and Disclaimer Statement This presentation contains forward - looking statements about our expectations, beliefs or intentions regarding, among other things, ou r product development efforts, busine
Safe Harbor and Disclaimer Statement This presentation contains forward - looking statements about our expectations, beliefs or intentions regarding, among other things, ou r product development efforts, business, financial condition, results of operations, strategies or prospect
Read more →GLMDGalmed Pharmaceuticals Ltd. Announces Proposed Public Offering of Ordinary Shares
TEL AVIV, Israel, June 18, 2018 /PRNewswire/ -- Galmed Pharmaceuticals Ltd. (NASDAQ: GLMD) ("Galmed" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of the liver targeted SCD1 modulator Aramchol™, a once-daily, oral therapy for the treatme
Read more →GLMDGalmed's 600 mg Aramchol™ Achieved a Regulatory Approvable Endpoint Showing NASH Resolution Without Worsening of Fibrosis, in NASH Patients, in the Global Phase 2b ARREST 52-Week Study Statistically significant reduction in liver fat was demonstrated by Magnetic Resonance Spectroscopy (MRS) in patients completing 52 weeks of...
TEL AVIV, Israel, June 12, 2018 /PRNewswire/ -- Statistically significant reduction in liver fat was demonstrated by Magnetic Resonance Spectroscopy (MRS) in patients completing 52 weeks of treatment with Aramchol 400mg vs. placebo. Post hoc analysis of MRS responders, defined b
Read more →GLMDGalmed Pharmaceuticals to Host Conference Call to Discuss Top-Line, 52-Week Results from the Global Phase 2b ARREST Study
TEL AVIV, Israel, June 11, 2018 /PRNewswire/ -- Galmed Pharmaceuticals Ltd. (Nasdaq: GLMD) ("Galmed" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of Aramchol™, an oral, once-daily, liver-targeted SCD1 modulator, for the treatment of non
Read more →GLMDGalmed Pharmaceuticals Provides Business Update and Reports First Quarter 2018 Financial Results
TEL AVIV, Israel, May 9, 2018 /PRNewswire/ --Galmed Pharmaceuticals Ltd. (Nasdaq: GLMD) ("Galmed" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of the liver targeted SCD1 modulator Aramchol™, a once-daily, oral therapy for the treatment
Read more →GLMDGalmed Pharmaceuticals to Report First Quarter 2018 Financial Results and Provide Business Update on Wednesday, May 9
TEL AVIV, Israel, May 1, 2018 /PRNewswire/ -- Galmed Pharmaceuticals Ltd. (Nasdaq: GLMD) ("Galmedˮ or the "Company"), a clinical-stage biopharmaceutical company focused on the development of the liver targeted SCD1 modulator Aramchol™, a once-daily, oral therapy for the treatment
Read more →GLMDGalmed Pharmaceuticals to Host Post-EASL Key Opinion Leader Call on the Scientific Rationale and Clinical Development of Aramchol™ for NASH
TEL AVIV, Israel, April 16, 2018 /PRNewswire/ -- Galmed Pharmaceuticals Ltd. (Nasdaq: GLMD) ("Galmed" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of the liver targeted SCD1 modulator Aramchol™, a once-daily, oral therapy for the treatm
Read more →GLMDGalmed Pharmaceuticals Announces Pricing of $6.0 Million Registered Direct Offering
TEL AVIV, Israel, April 3, 2018 /PRNewswire/ -- Galmed Pharmaceuticals Ltd. (Nasdaq: GLMD) ("Galmedˮ or the "Company"), a clinical-stage biopharmaceutical company focused on the development of the liver targeted SCD1 modulator Aramchol™, a once-daily, oral therapy for the treatme
Read more →GLMDGalmed Pharmaceuticals to Present New Scientific Data on the Mechanism by Which Aramchol Exerts its Effect on Fibrosis at EASL
TEL AVIV, Israel, March 27, 2018 /PRNewswire/ -- Galmed Pharmaceuticals Ltd. (Nasdaq: GLMD) ("Galmed" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of the liver targeted SCD1 modulator Aramchol™, a once-daily, oral therapy for the treat
Read more →GLMDGalmed Pharmaceuticals Reports Fourth Quarter and Full Year 2017 Financial Results and Provides Business Update
TEL AVIV, Israel, March 13, 2018 /PRNewswire/ -- Galmed Pharmaceuticals Ltd. (Nasdaq: GLMD) ("Galmedˮ or the "Company"), a clinical-stage biopharmaceutical company focused on the development of the liver targeted SCD1 modulator Aramchol™, a once-daily, oral therapy for the treatm
Read more →GLMDGalmed Pharmaceuticals to Report Full Year and Fourth Quarter 2017 Financial Results and Provide Business Update on Tuesday, March 13
TEL AVIV, Israel, March 5, 2018 /PRNewswire/ -- Galmed Pharmaceuticals Ltd. (Nasdaq: GLMD) ("Galmedˮ or the "Company"), a clinical-stage biopharmaceutical company focused on the development of the liver targeted SCD1 modulator Aramchol™, a once-daily, oral therapy for the treatm
Read more →GLMDGalmed Pharmaceuticals to Participate in Investor Conferences in March
TEL AVIV, Israel, Mar. 2, 2018 /PRNewswire/ -- Galmed Pharmaceuticals Ltd. (NASDAQ: GLMD) ("Galmedˮ or the "Companyˮ), a clinical-stage biopharmaceutical company focused on the development of the liver-targeted SCD1 modulator Aramchol™, a once-daily, oral therapy for the treatmen
Read more →GLMDGalmed Announces ARRIVE Study Data
Galmed Announces ARRIVE Study Data TEL AVIV, Israel, February 14, 2018 -- Galmed Pharmaceuticals Ltd. (Nasdaq: GLMD) ("Galmed or the "Company"), a clinical-stage biopharmaceutical company focused on the development of the liver targeted SCD1 modulator Aramchol , a once-daily,
Read more →GLMDGalmed Pharmaceuticals to Provide Corporate Update at the LEERINK Partners 7th Annual Global Healthcare Conference
TEL AVIV, Israel, Feb. 8, 2018 /PRNewswire/ -- Galmed Pharmaceuticals Ltd. (Nasdaq: GLMD) ("Galmedˮ or the "Companyˮ), a clinical-stage biopharmaceutical company focused on the development of Aramchol[TM], a once-daily, oral therapy, liver targeted SCD1 modulator, for the treatme
Read more →GLMDGalmed Granted "Preferred Technological Enterprise" Status Which may Provide the Company With Significant Financial Benefits
TEL AVIV, Israel, Feb. 7, 2018 /PRNewswire/ -- Galmed Pharmaceuticals, Ltd. (Nasdaq: GLMD), ("Galmed" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of a once-daily, oral therapy for the treatment of nonalcoholic steatohepatitis, or NASH
Read more →GLMDAramchol Treating NASH through prevention and reversal of fibrosis January 2018 "Safe Harbor" and Disclaimer Statement This presentation contains forward - looking statements about our expectations, beliefs or intentions
Aramchol Treating NASH through prevention and reversal of fibrosis January 2018 "Safe Harbor" and Disclaimer Statement This presentation contains forward - looking statements about our expectations, beliefs or intentions regarding, among other thing s, our product development ef
Read more →GLMDGalmed Pharmaceuticals Raised Gross Proceeds of $11.6 Million Under ATM Programs During December 2017
TEL AVIV, Israel, Jan. 2, 2018 /PRNewswire/ -- Galmed Pharmaceuticals Ltd. (Nasdaq: GLMD) ("Galmed" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of a once-daily, oral therapy for the treatment of nonalcoholic steatohepatitis, or NASH, a
Read more →GLMDGalmed Pharmaceuticals to Present at HEP DART 2017 Meeting
TEL AVIV, Israel, Nov. 27, 2017 /PRNewswire/ -- Galmed Pharmaceuticals Ltd. (Nasdaq: GLMD) ("Galmed" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of a once-daily, oral therapy for the treatment of nonalcoholic steatohepatitis, or NASH a
Read more →GLMDGalmed Pharmaceuticals Reports Third Quarter 2017 Financial Results and Provides Business Update
TEL AVIV, Israel, Nov. 9, 2017 /PRNewswire/ -- Galmed Pharmaceuticals Ltd. (Nasdaq: GLMD) ("Galmed" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of a once-daily, oral therapy for the treatment of nonalcoholic steatohepatitis, or NASH, a
Read more →GLMDGalmed Pharmaceuticals to Report Third Quarter Financial Results on Thursday, November 9th
TEL AVIV, Israel, Nov. 1, 2017 /PRNewswire/ -- Galmed Pharmaceuticals Ltd. (NASDAQ: GLMD), a clinical-stage biopharmaceutical company focused on the development of a once-daily, oral therapy for the treatment of nonalcoholic steatohepatitis, or NASH and other liver diseases, toda
Read more →GLMDGalmed Pharmaceuticals Announces Publication of Data on Aramchol™ Mechanism of Action in Hepatology Communications. Data Will Also Be Presented at AASLD
TEL AVIV, Israel, Oct. 5, 2017 /PRNewswire/ -- Galmed Pharmaceuticals, Inc. (GLMD), a clinical-stage biopharmaceutical company focused on the development of a once-daily, oral therapy for the treatment of nonalcoholic steatohepatitis, or NASH and other liver diseases, today annou
Read more →GLMDGalmed Pharmaceuticals Announces Pricing of Offering of Ordinary Shares to Existing Investors and Members of the Board of Directors
TEL AVIV, Israel, Aug. 3, 2017 /PRNewswire/ -- Galmed Pharmaceuticals Ltd. (Nasdaq: GLMD) ("Galmed" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of a once-daily, oral therapy for the treatment of nonalcoholic steatohepatitis, or NASH, a
Read more →GLMDGalmed Pharmaceuticals Reports Second Quarter 2017 Financial Results and Provides Business Update
TEL AVIV, Israel, July 31, 2017 /PRNewswire/ -- Galmed Pharmaceuticals Ltd. (Nasdaq: GLMD) ("Galmed" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of a once-daily, oral therapy for the treatment of nonalcoholic steatohepatitis, or NASH,
Read more →GLMDGalmed Pharmaceuticals Reports Second Quarter
Galmed Pharmaceuticals Reports Second Quarter 2017 Financial Results and Provides Business Update - Conference Call and Webcast Today at 8:30 a.m. EDT / 5:30 a.m. PDT - TEL AVIV, Israel, July 31, 2017 - Galmed Pharmaceuticals Ltd. (Nasdaq: GLMD) ("Galmed" or the "Company"),
Read more →GLMDGalmed Pharmaceuticals Second Quarter 2017 Conference Call and Webcast Scheduled for Monday, July 31, 2017
TEL AVIV, Israel, July 24, 2017 /PRNewswire/ -- Galmed Pharmaceuticals Ltd. (Nasdaq: GLMD) ("Galmed" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of a once-daily, oral therapy for the treatment of nonalcoholic steatohepatitis, or NASH,
Read more →GLMDGalmed Pharmaceuticals Announces the Election of Dr. Carol L. Brosgart as a New Member of the Board of Directors
TEL AVIV, Israel, June 8, 2017 /PRNewswire/ -- Galmed Pharmaceuticals Ltd. (Nasdaq: GLMD) ("Galmed" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of a once-daily, oral therapy for the treatment of nonalcoholic steatohepatitis, or NASH, a
Read more →GLMDGalmed Pharmaceuticals Reports First Quarter 2017 Financial Results
TEL AVIV, Israel, May 15, 2017 /PRNewswire/ -- Galmed Pharmaceuticals Ltd. (Nasdaq: GLMD) ("Galmed" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of a once-daily, oral therapy for the treatment of nonalcoholic steatohepatitis, or NASH, a
Read more →GLMDGalmed Pharmaceuticals First Quarter 2017 Conference Call and Webcast Scheduled for Monday, May 15th, 2017
TEL AVIV, Israel, May 8, 2017 /PRNewswire/ -- Galmed Pharmaceuticals Ltd. (Nasdaq: GLMD) ("Galmed" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of a once-daily, oral therapy for the treatment of nonalcoholic steatohepatitis, or NASH, an
Read more →GLMDGalmed Pharmaceuticals to Present at International Liver Congress Data that Shows Aramchol TM has a Potential Direct Effect on Liver Fibrosis
Pharmaceuticals to Present at International Liver Congress Data that Shows AramcholTM has a Potential Direct Effect on Liver Fibrosis TEL AVIV, Israel, April 5, 2017 - Galmed Pharmaceuticals Ltd. (Nasdaq: GLMD) ("Galmed" or the "Company"), a clinical-stage biopharmaceutical c
Read more →GLMDGalmed Pharmaceuticals Reports Fourth Quarter and Full Year 2016 Financial Results
TEL AVIV, Israel, March 23, 2017 /PRNewswire/ -- Galmed Pharmaceuticals Ltd. (Nasdaq: GLMD) ("Galmed" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of a once-daily, oral therapy for the treatment of nonalcoholic steatohepatitis, or NASH,
Read more →GLMDGalmed Pharmaceuticals Fourth Quarter 2016 Conference Call and Webcast Scheduled for Thursday, March 23rd, 2017
TEL AVIV, Israel, March 16, 2017 /PRNewswire/ -- Galmed Pharmaceuticals Ltd. (Nasdaq: GLMD) ("Galmed" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of a once-daily, oral therapy for the treatment of nonalcoholic steatohepatitis, or NASH,
Read more →GLMDGalmed Pharmaceuticals Completes Patient Recruitment for ARREST Phase IIb NASH study
TEL AVIV, Israel,, Jan 9, 2017 /PRNewswire/ -- Galmed Pharmaceuticals Ltd. (Nasdaq: GLMD) ("Galmed" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of Aramchol, a once-daily, oral therapy for the treatment of liver diseases including Non-A
Read more →GLMDGalmed Pharmaceuticals Reports Third Quarter 2016 Financial Results and Provides Business Update
TEL AVIV, Israel, Nov. 7, 2016 /PRNewswire/ -- Galmed Pharmaceuticals Ltd. (Nasdaq: GLMD) ("Galmed" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of a once-daily, oral therapy for the treatment of nonalcoholic steatohepatitis, or NASH, a
Read more →GLMDGalmed Pharmaceuticals Third Quarter 2016 Conference Call and Webcast Scheduled for Monday, November 7th, 2016
TEL AVIV, Israel, Oct. 31, 2016 /PRNewswire/ -- Galmed Pharmaceuticals Ltd. (Nasdaq: GLMD) ("Galmed" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of a once-daily, oral therapy for the treatment of liver diseases, announced today that it
Read more →GLMDPharmaceuticals Announces that it has Raised Approximately
Pharmaceuticals Announces that it has Raised Approximately $5.0 Million to Date Under its ATM Program TEL AVIV, Israel, September 29, 2016 - Galmed Pharmaceuticals Ltd. (Nasdaq: GLMD) ("Galmed" or the "Company"), a clinical-stage biopharmaceutical company focused on the devel
Read more →GLMDGalmed Pharmaceuticals Announces that it has Raised Approximately $5.0 Million to Date Under its ATM Program
TEL AVIV, Israel, Sept. 29, 2016 /PRNewswire/ -- Galmed Pharmaceuticals Ltd. (Nasdaq: GLMD) ("Galmed" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of a once-daily, oral therapy for the treatment of liver diseases, announced today that,
Read more →GLMDGalmed Pharmaceuticals and the University of California, San Diego Enter into an Investigator-Initiated Clinical Trial Agreement to Assess Aramchol™ Effects Juvenile Population
TEL AVIV, Israel, Sept. 22, 2016 /PRNewswire/ -- Galmed Pharmaceuticals Ltd. (Nasdaq: GLMD) ("Galmed" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of a once-daily, oral therapy for the treatment of liver diseases, today announced that i
Read more →GLMDPharmaceuticals Announces the Appointment of Dr.
Pharmaceuticals Announces the Appointment of Dr. Liat Hayardeny, Ph.D. MBA, as Chief Scientific Officer CSO Position Aimed Towards Expanding Therapeutic Potential of AramcholTM - AVIV, Israel, September 8, 2016 - Galmed Pharmaceuticals Ltd. (Nasdaq: GLMD) ("Galmed" or the "Com
Read more →GLMDGalmed Pharmaceuticals Announces the Appointment of Dr. Liat Hayardeny, Ph.D. MBA, as Chief Scientific Officer
TEL AVIV, Israel, Sept. 8, 2016 /PRNewswire/ -- Galmed Pharmaceuticals Ltd. (Nasdaq: GLMD) ("Galmed" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of a once-daily, oral therapy for the treatment of liver diseases, today announced that it
Read more →GLMDPharmaceuticals Reports Second Quarter 2016 Financial Results and Provides Business Update
Pharmaceuticals Reports Second Quarter 2016 Financial Results and Provides Business Update - Conference Call and Webcast Today at 8:30 a.m. EDT / 5:30 a.m. PDT - TEL AVIV, Israel, August 3, 2016 - Galmed Pharmaceuticals Ltd. (Nasdaq: GLMD) ("Galmed" or the "Company"), a clini
Read more →GLMDGalmed Pharmaceuticals Reports Second Quarter 2016 Financial Results and Provides Business Update
TEL AVIV, Israel, Aug. 3, 2016 /PRNewswire/ -- Galmed Pharmaceuticals Ltd. (Nasdaq: GLMD) ("Galmed" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of a once-daily, oral therapy for the treatment of liver diseases, today reported financial
Read more →GLMDAnnounces the Appointment of
Galmed Pharmaceuticals Announces the Appointment of Ran Oren, M.D., as Chief Medical Officer TEL AVIV, Israel, August 1, 2016 - Galmed Pharmaceuticals Ltd. (Nasdaq: GLMD) ("Galmed" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of a
Read more →GLMDGalmed Pharmaceuticals Announces the Appointment of Professor Ran Oren, M.D., as Chief Medical Officer
TEL AVIV, Israel, Aug. 1, 2016 /PRNewswire/ -- Galmed Pharmaceuticals Ltd. (Nasdaq: GLMD) ("Galmed" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of a once-daily, oral therapy for the treatment of liver diseases, announced today that it
Read more →GLMDGalmed Pharmaceuticals and SAMIL Pharm Sign a License Agreement for the Commercialization of Aramchol™ in Korea
TEL AVIV, Israel, July 28, 2016 /PRNewswire/ -- Galmed Pharmaceuticals Ltd. (Nasdaq: GLMD) ("Galmed" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of a once-daily, oral therapy for the treatment of liver diseases, and SAMIL Pharm. Co., L
Read more →GLMDGalmed Pharmaceuticals Second Quarter 2016 Conference Call and Webcast Scheduled for Wednesday, August 3rd, 2016
TEL AVIV, Israel, July 27, 2016 /PRNewswire/ -- Galmed Pharmaceuticals Ltd. (Nasdaq: GLMD) ("Galmed" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of a once-daily, oral therapy for the treatment of liver diseases, announced today that it
Read more →GLMDGalmed Pharmaceuticals and Weizmann Institute of Science to enter a research collaboration agreement to assess Aramchol™ effects on microbiome
TEL AVIV, Israel, June 30, 2016 /PRNewswire/ -- Galmed Pharmaceuticals Ltd. (Nasdaq: GLMD) ("Galmed" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of a once-daily, oral therapy for the treatment of liver diseases, announced today that it
Read more →GLMDGalmed Pharmaceuticals Expands its Ongoing Phase IIb ARREST Study to China
TEL AVIV, Israel, June 7, 2016 /PRNewswire/ -- Galmed Pharmaceuticals Ltd. (Nasdaq: GLMD) ("Galmed" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of a once-daily, oral therapy for the treatment of liver diseases, announced today that it
Read more →GLMDGalmed Pharmaceuticals Randomizes 120th Patient in the ARREST Trial
TEL AVIV, Israel, June 1, 2016 /PRNewswire/ -- Galmed Pharmaceuticals Ltd. (Nasdaq: GLMD) ("Galmed" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of a once-daily, oral therapy for the treatment of liver diseases, today announced that it
Read more →GLMDGalmed Pharmaceuticals Reports First Quarter 2016 Financial Results and Provides Business Update
TEL AVIV, Israel, May 16, 2016 /PRNewswire/ -- Galmed Pharmaceuticals Ltd. (Nasdaq: GLMD) ("Galmed" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of a once-daily, oral therapy for the treatment of liver diseases, today reported financial
Read more →GLMDGalmed Pharmaceuticals First Quarter 2016 Conference Call and Webcast Scheduled for Monday, May 16th, 2016
TEL AVIV, Israel, May 9, 2016 /PRNewswire/ -- Galmed Pharmaceuticals Ltd. (Nasdaq: GLMD) ("Galmed" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of a once-daily, oral therapy for the treatment of liver diseases, announced today that it w
Read more →GLMDMount Sinai and Galmed Pharmaceuticals to Collaborate in an Investigator Initiated Phase IIa Trial to Evaluate the Effect of AramcholTM in Combination with Vitamin D for the Treatment of Patients with Fibrotic Nonalcoholic Fatty Liver Disease
TEL AVIV, Israel, May 3, 2016 /PRNewswire/ -- Galmed Pharmaceuticals Ltd. (Nasdaq: GLMD) ("Galmed" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of a once-daily, oral therapy for the treatment of liver diseases, announced today that it h
Read more →GLMDGalmed Pharmaceuticals to Hold a Symposium on Non-Invasive Diagnostics during the International Liver Congress in Spain
TEL AVIV, Israel, April 7, 2016 /PRNewswire/ -- Galmed Pharmaceuticals Ltd. (Nasdaq: GLMD) ("Galmed" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of a once-daily, oral therapy for the treatment of liver diseases, announced today that it
Read more →GLMDAramchol TM Demonstrates Significant Anti-Fibrotic Effect in a Pre-clinical Model of Fatty Liver Disease
AramcholTM Demonstrates Significant Anti-Fibrotic Effect in a Pre-clinical Model of Fatty Liver Disease TEL AVIV, Israel, March 30, 2016 - Galmed Pharmaceuticals Ltd. (Nasdaq: GLMD) ("Galmed" or the "Company"), a clinical-stage biopharmaceutical company focused on the develo
Read more →GLMDAramchol™ Demonstrates Significant Anti-Fibrotic Effect in a Pre-clinical Model of Fatty Liver Disease
TEL AVIV, Israel, March 30, 2016 /PRNewswire/ -- Galmed Pharmaceuticals Ltd. (Nasdaq: GLMD) ("Galmed" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of a once-daily, oral therapy for the treatment of liver diseases, announced today pre-cl
Read more →GLMDGalmed Pharmaceuticals Reports Full Year 2015 Financial Results and Provides Business Update
TEL AVIV, Israel, March 22, 2016 /PRNewswire/ -- Galmed Pharmaceuticals Ltd. (Nasdaq: GLMD) ("Galmed" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of a once-daily, oral therapy for the treatment of liver diseases, today reported financi
Read more →GLMDGalmed Pharmaceuticals Fourth Quarter 2015 Conference Call and Webcast Scheduled for Tuesday, March 22nd, 2016
Galmed Pharmaceuticals Ltd. logo TEL AVIV, Israel, March 15, 2016 /PRNewswire/ -- Galmed Pharmaceuticals Ltd. (Nasdaq: GLMD) ("Galmed" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of a once-daily, oral therapy for the treatment of live
Read more →GLMDGalmed Pharmaceuticals to Present at the ROTH Conference
Galmed Pharmaceuticals Ltd. logo TEL AVIV, Israel, March 7, 2016 /PRNewswire/ -- Galmed Pharmaceuticals Ltd. (Nasdaq: GLMD) ("Galmed" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of a once-daily, oral therapy for the treatment of liver
Read more →GLMDGalmed Pharmaceuticals Announces the Enrollment of the First Patient in the ARRIVE Study
Galmed Pharmaceuticals Ltd. logo TEL AVIV, Israel, March 1, 2016 /PRNewswire/ -- Galmed Pharmaceuticals Ltd. (Nasdaq: GLMD) ("Galmed" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of a once-daily, oral therapy for the treatment of liver
Read more →GLMDGalmed Pharmaceuticals Announces Retirement of Chief Medical Officer
Galmed Pharmaceuticals Ltd. logo TEL AVIV, Israel, Feb. 11, 2016 /PRNewswire/ -- Galmed Pharmaceuticals Ltd. (Nasdaq: GLMD) (the "Company"), a clinical-stage biopharmaceutical company focused on the development of a once-daily, oral therapy for the treatment of liver diseases, a
Read more →GLMDGalmed Pharmaceuticals to Present at the Biotech Showcase™
TEL AVIV, Israel, Jan. 5, 2016 /PRNewswire/ -- Galmed Pharmaceuticals Ltd. (Nasdaq: GLMD) ("Galmed" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of a once-daily, oral therapy for the treatment of liver diseases, today announced that Jos
Read more →GLMDGalmed Pharmaceuticals Announces FDA Clearance of IND of Aramachol™ for the Treatment of Patients with HIV-Associated Lipodystrophy and Nonalcoholic Fatty Liver Disease
TEL AVIV, Israel, Dec. 1, 2015 /PRNewswire/ -- Galmed Pharmaceuticals Ltd. (Nasdaq: GLMD) ("Galmed" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of a once-daily, oral therapy for the treatment of liver diseases, announced today that the
Read more →GLMDGalmed Pharmaceuticals Announces Commencement of Patient Screening for the ARREST Study in Europe, and Reports Third Quarter 2015 Financial Results
TEL AVIV, Israel, Nov. 9, 2015 /PRNewswire/ -- Galmed Pharmaceuticals Ltd. (Nasdaq: GLMD) ("Galmed" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of a once-daily, oral therapy for the treatment of liver diseases, today announced the comm
Read more →GLMDGalmed Pharmaceuticals Third Quarter 2015 Conference Call and Webcast Scheduled for November 9, 2015
Galmed Pharmaceuticals Ltd. logo TEL AVIV, Israel, Nov. 2, 2015 /PRNewswire/ -- Galmed Pharmaceuticals Ltd. (Nasdaq: GLMD) ("Galmed"), a clinical-stage biopharmaceutical company focused on the development and commercialization of a once-daily, oral therapy for the treatment of l
Read more →GLMDGalmed Pharmaceuticals Announces the Commencement of Patient Screening in the ARREST Study in the United States and Latin America, and Reports Second Quarter 2015 Financial Results - Conference Call and Webcast Today at
Galmed Pharmaceuticals Announces the Commencement of Patient Screening in the ARREST Study in the United States and Latin America, and Reports Second Quarter 2015 Financial Results - Conference Call and Webcast Today at 8:30 a.m. EDT / 5:30 a.m. PDT - TEL AVIV, Israel, Augu
Read more →GLMDGalmed Pharmaceuticals Unfolds the Development of Aramchol™ Non-Invasive Companion Diagnostic Program
TEL AVIV, Israel, July 8, 2015 /PRNewswire/ -- Galmed Pharmaceuticals Ltd. (Nasdaq: GLMD) ("Galmed"), a clinical-stage biopharmaceutical company focused on the development and commercialization of a once-daily, oral therapy for the treatment of liver diseases, announced today tha
Read more →GLMDGalmed Pharmaceuticals Reports First Quarter 2015 Financial Results and Provides Business Update
TEL AVIV, Israel, May 13, 2015 /PRNewswire/ -- Galmed Pharmaceuticals Ltd. (Nasdaq: GLMD) ("Galmed" or the "Company"), a clinical-stage biopharmaceutical company focused on the development and commercialization of a once-daily, oral therapy for the treatment of liver diseases, to
Read more →GLMDGalmed Pharmaceuticals First Quarter 2015 Conference Call and Webcast Scheduled for Wednesday, May 13, 2015
TEL AVIV, Israel, May 6, 2015 /PRNewswire/ -- Galmed Pharmaceuticals Ltd. (Nasdaq: GLMD) ("Galmed"), a clinical-stage biopharmaceutical company focused on the development and commercialization of a once-daily, oral therapy for the treatment of liver diseases and cholesterol galls
Read more →GLMDGALMED PHARMACEUTICALS LTD. 8 Shaul Hamelech Blvd. Amot Mishpat Bldg. Tel Aviv, Israel 6473307
GALMED PHARMACEUTICALS invited to attend an Annual General Meeting of Shareholders of Galmed Pharmaceuticals Ltd. to be held at 1:00 p.m., Israel time, on Monday, May 11, 2015, at the offices of Tulchinsky Stern Marciano Cohen Levitski & Co., 4 Berkowitz Street, Museum Tower,
Read more →GLMDGalmed Pharmaceuticals Announces the Appointment of George Tonelli as Vice President of Clinical Operations
TEL AVIV, Israel, April 1, 2015 /PRNewswire/ -- Galmed Pharmaceuticals Ltd. (Nasdaq: GLMD) ("Galmed"), a clinical-stage biopharmaceutical company focused on the development and commercialization of a once-daily, oral therapy for the treatment of liver diseases and cholesterol gal
Read more →GLMDGalmed Pharmaceuticals Reports Full Year 2014 Financial Results and Provides Business Update
TEL AVIV, Israel, March 31, 2015 /PRNewswire/ -- Galmed Pharmaceuticals Ltd. (Nasdaq: GLMD) ("Galmed"), a clinical-stage biopharmaceutical company focused on the development and commercialization of a once-daily, oral therapy for the treatment of liver diseases and cholesterol ga
Read more →GLMDGalmed Pharmaceuticals Fourth Quarter 2014 Conference Call and Webcast Scheduled for Tuesday, March 31, 2015
TEL AVIV, Israel, March 24, 2015 /PRNewswire/ -- Galmed Pharmaceuticals Ltd. (Nasdaq: GLMD) ("Galmed"), a clinical-stage biopharmaceutical company focused on the development and commercialization of a once-daily, oral therapy for the treatment of liver diseases and cholesterol ga
Read more →GLMDGalmed Pharmaceuticals to Present at the Metabolic Leaders
TEL AVIV, Israel, March 17, 2015 /PRNewswire/ -- Galmed Pharmaceuticals Ltd. (Nasdaq: GLMD) ("Galmed"), a clinical-stage biopharmaceutical company focused on the development and commercialization of a once-daily, oral therapy for the treatment of liver diseases and cholesterol ga
Read more →GLMDGalmed Pharmaceuticals Announces the Beginning of Enrollment in its Phase IIb ARREST Trial for the Treatment of NASH, as well as the Expansion of the Study to the United States
TEL AVIV, Israel, March 9, 2015 /PRNewswire/ -- Galmed Pharmaceuticals Ltd. (Nasdaq: GLMD) ("Galmed"), a clinical-stage biopharmaceutical company focused on the development and commercialization of a once-daily, oral therapy for the treatment of liver diseases and cholesterol gal
Read more →GLMDGalmed Pharmaceuticals to Present at the 27th Annual ROTH Conference
TEL AVIV, Israel, March 2, 2015 /PRNewswire/ -- Galmed Pharmaceuticals Ltd. (Nasdaq: GLMD) ("Galmed"), a clinical-stage biopharmaceutical company focused on the development and commercialization of a once-daily, oral therapy for the treatment of liver diseases and cholesterol gal
Read more →GLMDGalmed Pharmaceuticals to Present at the European Fatty Liver Conference
TEL AVIV, Israel, Feb. 25, 2015 /PRNewswire/ -- Galmed Pharmaceuticals Ltd. (Nasdaq: GLMD) ("Galmed"), a clinical-stage biopharmaceutical company focused on the development and commercialization of a once-daily, oral therapy for the treatment of liver diseases and cholesterol gal
Read more →GLMDGalmed and Perrigo Execute Manufacturing Agreement for Large-Scale Aramchol API Production
TEL-AVIV, Israel, Jan. 28, 2015 /PRNewswire/ -- Galmed Pharmaceuticals Ltd. (Nasdaq: GLMD) ("Galmed"), a clinical-stage biopharmaceutical company focused on the development and commercialization of a once-daily, oral medication for the treatment of liver diseases and cholesterol
Read more →GLMDand Perrigo Execute Manufacturing Agreement
and Perrigo Execute Manufacturing Agreement for Large-Scale Aramchol API Production TEL-AVIV, Israel, January 28, 2015 /PRNewswire/ - Galmed Pharmaceuticals Ltd. (Nasdaq: GLMD) ("Galmed"), a clinical-stage biopharmaceutical company focused on the development and commercializa
Read more →GLMDGalmed Pharmaceuticals Announces the Appointment of Josh Blacher as Chief Financial Officer
TEL AVIV, Israel, Jan. 5, 2015 /PRNewswire/ -- Galmed Pharmaceuticals Ltd. (Nasdaq: GLMD) ("Galmed"), a clinical-stage biopharmaceutical company focused on the development and commercialization of a once-daily, oral therapy for the treatment of liver diseases and cholesterol gall
Read more →GLMDGalmed Pharmaceuticals Completes Analysis of a Pharmacokinetic Study of Aramchol in Healthy Volunteers
TEL AVIV, Israel, Dec. 1, 2014 /PRNewswire/ -- Galmed Pharmaceuticals Ltd. (Nasdaq: GLMD) ("Galmed"), a clinical-stage biopharmaceutical company focused on the development and commercialization of a once-daily, oral therapy for the treatment of liver diseases and cholesterol gall
Read more →GLMDGalmed Pharmaceuticals Announces First Administration of Aramchol in its Phase IIa Trial for the Treatment of Cholesterol Gallstones
TEL AVIV, Israel, Nov. 13, 2014 /PRNewswire/ -- Galmed Pharmaceuticals Ltd. (Nasdaq: GLMD) ("Galmed"), a clinical-stage biopharmaceutical company focused on the development and commercialization of a once-daily, oral medication for the treatment of liver diseases and cholesterol
Read more →GLMDGalmed Pharmaceuticals Provides Business Update and Reports Year-To-Date 2014 Financial Results
TEL AVIV, Israel, Nov. 12, 2014 /PRNewswire/ -- Galmed Pharmaceuticals Ltd. (Nasdaq: GLMD) ("Galmed"), a clinical-stage biopharmaceutical company focused on the development and commercialization of a once-daily, oral therapy for the treatment of liver diseases and cholesterol gal
Read more →GLMDGALMED PHARMACEUTICALS LTD. 8 Shaul Hamelech Blvd., Amot Hamishpat Bldg., Tel Aviv, Israel 64733
GALMED PHARMACEUTICALS LTD. 8 Shaul Hamelech Blvd., Amot Hamishpat Bldg., Tel Aviv, Israel 64733 You are cordially invited to attend a Special General Meeting of Shareholders of Galmed Pharmaceuticals Ltd. to be held at 12:00 p.m., Israel time, on Monday, December 15, 2014, at t
Read more →GLMDGalmed Pharmaceuticals to Host Key Opinion Leader Meeting and Webcast on November 7, 2014 in New York City
TEL AVIV, Israel, Nov. 5, 2014 /PRNewswire/ -- Galmed Pharmaceuticals Ltd. (Nasdaq: GLMD) ("Galmed"), a clinical-stage biopharmaceutical company focused on the development and commercialization of a once-daily, oral medication for the treatment of liver diseases and cholesterol g
Read more →GLMDGalmed Pharmaceuticals Third Quarter 2014 Conference Call and Webcast Scheduled for Wednesday, November 12, 2014
TEL AVIV, Israel, Nov. 5, 2014 /PRNewswire/ -- Galmed Pharmaceuticals Ltd. (Nasdaq: GLMD) ("Galmed"), a clinical-stage biopharmaceutical company focused on the development and commercialization of a once-daily, oral therapy for the treatment of liver diseases and cholesterol gall
Read more →GLMDGalmed Pharmaceuticals and Itamar Medical to Collaborate on Assessing Aramchol
TEL-AVIV, Israel, Sept. 29, 2014 /PRNewswire/ -- Galmed Pharmaceuticals Ltd. (Nasdaq: GLMD) ("Galmed"), a clinical-stage biopharmaceutical company focused on the development and commercialization of a once-daily, oral medication for the treatment of liver diseases and cholesterol
Read more →GLMDGalmed Pharmaceuticals Announces U.S. FDA Approval of Fast Track Designation of Aramchol for the Treatment of NASH
TEL AVIV, Israel, Sept. 23, 2014 /PRNewswire/ -- Galmed Pharmaceuticals Ltd. (Nasdaq:GLMD) ("Galmed"), a clinical-stage biopharmaceutical company focused on the development and commercialization of a once-daily, oral therapy for the treatment of liver diseases and cholesterol gal
Read more →GLMDGalmed Pharmaceuticals Completes Two Chronic Toxicology Studies and Reports No Significant Adverse Events
TEL-AVIV, Israel, Sept. 2, 2014 /PRNewswire/ -- Galmed Pharmaceuticals Ltd. (Nasdaq: GLMD) ("Galmed"), a clinical-stage biopharmaceutical company focused on the development and commercialization of a once-daily, oral therapy for the treatment of liver diseases and cholesterol gal
Read more →GLMDGalmed Pharmaceuticals Reports First Half 2014 Financial Results
TEL AVIV, Israel, July 25, 2014 /PRNewswire/ -- Galmed Pharmaceuticals Ltd. (Nasdaq: GLMD) (Galmed), a clinical-stage biopharmaceutical company focused on the development and commercialization of a once-daily, oral therapy for the treatment of liver diseases and cholesterol galls
Read more →GLMDGalmed Announces FDA Clearance of IND of Aramchol for the Treatment of Fatty Liver Disorders
Galmed Announces FDA Clearance of IND for the Treatment of Fatty Liver Disorders TEL AVIV, Israel-July 22, 2014-Galmed Pharmaceuticals Ltd. (Nasdaq:GLMD) ("Galmed"), a clinical-stage biopharmaceutical company focused on the development and commercialization of a once-daily, o
Read more →GLMDGalmed Announces FDA Clearance of IND of Armachol for the Treatment of Fatty Liver Disorders
TEL AVIV, Israel, July 22, 2014 /PRNewswire/ -- Galmed Pharmaceuticals Ltd. (Nasdaq: GLMD) ("Galmed"), a clinical-stage biopharmaceutical company focused on the development and commercialization of a once-daily, oral therapy for the treatment of liver diseases and cholesterol gal
Read more →GLMDGalmed Pharmaceuticals Second Quarter 2014 Conference Call and Webcast Scheduled for Friday, July 25, 2014
TEL AVIV, Israel, July 21, 2014 /PRNewswire/ -- Galmed Pharmaceuticals Ltd. (Nasdaq: GLMD) ("Galmed"), a clinical-stage biopharmaceutical company focused on the development and commercialization of a once-daily, oral therapy for the treatment of liver diseases and cholesterol gal
Read more →GLMDGalmed Announces Publication of Aramchol Phase IIa Trial in the Clinical Gastroenterology and Hepatology Journal
TEL AVIV, Israel, July 8, 2014 /PRNewswire/ -- Galmed Pharmaceuticals Ltd. (Nasdaq:GLMD) ("Galmed") today announced the recent publication of the results of its Phase IIa clinical trial of aramchol in the peer-reviewed Clinical Gastroenterology and Hepatology Journal. The trial
Read more →GLMDGalmed Pharmaceuticals Announces the Filing of a Provisional Patent Application for the Use of Aramchol for the Treatment of Lipodystrophy
Galmed Pharmaceuticals Announces the Filing of a Provisional Patent Application for the Use of Aramchol for the Treatment of Lipodystrophy TEL AVIV, Israel, June 9, 2014 - Galmed Pharmaceuticals Ltd. (Nasdaq: GLMD) ("Galmed"), a clinical-stage biopharmaceutical company focused
Read more →GLMDRecently Published Independent Research Supports the Importance of Reverse Cholesterol Transport on NASH Pathogenesis
Recently Published Independent Research Supports the Importance of Reverse Cholesterol Transport on NASH Pathogenesis TEL AVIV, Israel, June 4, 2014 - Galmed Pharmaceuticals Ltd. (Nasdaq: GLMD) ("Galmed"), a clinical-stage biopharmaceutical company focused on the development
Read more →GLMDGalmed Pharmaceuticals Reports First Quarter 2014 Financial Results
TEL AVIV, Israel, May 15, 2014 /PRNewswire/ -- Galmed Pharmaceuticals Ltd. (Nasdaq:GLMD) ("Galmed"), a clinical-stage biopharmaceutical company focused on the development and commercialization of a once-daily, oral therapy for the treatment of liver diseases and cholesterol galls
Read more →GLMDGALMED PHARMACEUTICALS LTD. 8 Shaul Hamelech Blvd., Tel Aviv 6473307, Israel
GALMED PHARMACEUTICALS LTD. 8 Shaul Hamelech Blvd., Tel Aviv 6473307, invited to attend a Special General Meeting of Shareholders of Galmed Pharmaceuticals Ltd. to be held at 4:00 p.m., Israel time, on Thursday, June 12, 2014, at the Company's offices at 8 Shaul Hamelech Blvd.
Read more →GLMDGalmed Pharmaceuticals Commences Patient Screening for Aramchol Pharmacokinetic and Food Effect Studies
TEL AVIV, Israel, April 28, 2014 /PRNewswire/ -- Galmed Pharmaceuticals Ltd. (Nasdaq: GLMD) ("Galmed"), a clinical-stage biopharmaceutical company focused on the development and commercialization of a once-daily, oral therapy for the treatment of liver diseases and cholesterol ga
Read more →GLMDGalmed Pharmaceuticals Announces Closing of Initial Public Offering and Full Exercise of Underwriters
TEL AVIV, Israel, March 18, 2014 /PRNewswire/ -- Galmed Pharmaceuticals Ltd. (Nasdaq: GLMD) ("Galmed") today announced the closing of its initial public offering of 3,263,010 ordinary shares at a public offering price of $13.50 per share, which included 425,610 ordinary shares is
Read more →GLMDGalmed Pharmaceuticals Announces Closing of Initial Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares TEL AVIV, Israel--(PRNewswire) -- Galmed Pharmaceuticals Ltd. (Nasdaq:GLMD) ("Ga
Galmed Pharmaceuticals Announces Closing of Initial Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares TEL AVIV, Israel--(PRNewswire) -- Galmed Pharmaceuticals Ltd. (Nasdaq:GLMD) ("Galmed") today announced the closing of its initial public
Read more →GLMDGalmed Pharmaceuticals Announces Pricing of Initial Public Offering TEL AVIV, Israel--(PRNewswire)
Galmed Pharmaceuticals Announces Pricing of Initial Public Offering TEL AVIV, Israel--(PRNewswire)-March 12, 2014-Galmed Pharmaceuticals Ltd. ("Galmed") today announced the pricing of its initial public offering of 2,837,400 ordinary shares at a public offering price of $13.5
Read more →Competitive Position
How GLMD ranks across every disease it competes inCompetitive Position is a premium feature
See how GLMD ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial